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There has been a recent explosion of genomics data in muscle-invasive
bladder cancer (MIBC) to better understand the underlying biology of the disease
that leads to the high amount of heterogeneity that is seen clinically. These studies
have identified relatively stable intrinsic molecular subtypes of MIBC that show
similarities to the basal and luminal subtypes of breast cancer. However, previous
studies have primarily focused on protein-coding genes or DNA
mutations/alterations.
There is emerging evidence implicating non-coding RNAs (ncRNAs), both
short (miRNA) and long (lncRNA), in the regulation of various biological processes
involved in cancer development and progression. The molecular mechanisms of
miRNAs are relatively straightforward by inhibiting their mRNA targets, but the
molecular mechanisms of lncRNAs are largely unknown. The identification of
miRNAs and lncRNAs that contribute to the gene expression patterns of basal and
luminal subtypes of MIBC will add another layer of subtype regulation.
In this work, we sought to study the differences in miRNA and lncRNA
expression across the subtypes of MIBC. We started with TCGA’s cohort of 408
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tumors as a discovery cohort to identify differentially expressed miRNAs and
lncRNAs that were specific to the basal and luminal subtypes of MIBC. We
developed our own miRNA-sequencing data set to perform validation studies, and
we found that the mRNA targets of the differentially expressed miRNAs were highly
reminiscent of the already known basal and luminal subtype biology. We also
developed bioinformatic analyses to extract lncRNA expression data that was used
for unsupervised consensus clustering. Surprisingly, unsupervised analyses of the
lncRNA expression data revealed two distinct clusters that exhibited more than 90%
concordance with the subtype classifications made using mRNA expression data.
Taken together, the results presented here suggest that miRNA expression
profiles, or lncRNA expression profiles, could be used as an alternative strategy to
identify MIBC subtype. These findings could have significant clinical implications in
the development of diagnostic tools for MIBC since miRNAs and lncRNAs are both
stably expressed in body fluids.
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Chapter 1: Introduction
Background & Rationale
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1. Introduction

1.1.

Bladder Cancer

The bladder is a hollow organ that is made up of four different layers, which
contain different cell types. These four layers include, from innermost to outermost,
the transitional epithelium (or urothelium), a layer of connective tissue, a layer of
muscle, and a layer of fatty connective tissue (Figure 1) (1). The majority of bladder
cancers are transitional cell carcinomas (or urothelial carcinomas) because they
arise from transitional cells in the transitional epithelium (1).
Bladder cancers can develop into either non-muscle invasive bladder cancers
(NMIBCs) or muscle invasive bladder cancers (MIBCs). NMIBCs are confined to the
transitional epithelium and connective tissue layer, and can either grow into the
hollow center of the bladder, referred to as papillary tumors (Figure 1), or can remain
as a flat tumor (Figure 1). MIBCs typically appear as flat tumors that progress to
invade through the other layers of the bladder, and can eventually spread outside of
the bladder to nearby lymph nodes, lungs, bones or liver.
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Figure 1: Illustration of the bladder wall. The four layers of the bladder wall are
depicted: transitional epithelium (urothelium), connective tissue, muscle, and fatty
layer. Papillary tumors are shown to grow into the hollow center of the bladder,
while flat tumors do not, but have a propensity to invade into the deeper layers of the
bladder wall.
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1.1.1. Staging
Bladder cancers are staged based on the amount of spread into the different
layers of the bladder. Non-invasive papillary carcinoma (Ta), non-invasive
carcinoma in situ (Tis), and tumors that have grown into the connective tissue layer
(T1) are all considered NMIBC. Tumors that have grown into the muscle layer (T2),
into the layer of fatty tissue (T3), or have spread to nearby organs (T4) are all
considered MIBC.

1.1.2. Statistics
Bladder cancer is the fourth most common cancer in men, occurring less
frequently in women, accounting for 5% of all new cancer cases in the United States.
For the year 2017, the American Cancer Society estimates 79,030 new bladder
cancer cases in the United States, and 16,870 bladder cancer related deaths.
The 5-year relative survival outcomes for patients with bladder cancer vary from
about 90% to 15% depending on the stage of the cancer (1). Approximately 70% of
bladder cancer cases are NMIBC, with roughly 25% of those progressing to develop
into MIBC. Patients with NMIBC have very good survival outcomes, with a 5-year
relative survival rate around 90%, but require long-term clinical management of the
disease as they are prone to recurrence (2). On the other hand, patients with MIBC
exhibit a more heterogeneous spread with 5-year relative survival rates ranging from
63% to 15% (3).
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1.1.3. Treatment
Bladder cancers can be treated with surgery alone or combined with other
treatments, such as immunotherapy or chemotherapy. Surgery alone is often
performed to treat NMIBCs, however new cancers can arise later in life. MIBCs are
typically treated with a combination of platinum-based chemotherapy either before
(neoadjuvant) or after (adjuvant) radical cystectomy (3, 4). Unfortunately, only about
30% to 40% of patients respond to this treatment plan, and the only alternative
strategy is a recently approved anti-PDL1 immune checkpoint inhibitor (5, 6).
Therefore, it is important to develop new classification systems, and identify new
treatable targets, to inform and improve the clinical management of the disease.

1.1.4. Disease Characterization
Several studies have shown that various gene signatures can predict tumor
stage, metastasis and progression, however the prognostication of bladder cancer is
largely based on pathological criteria (7). Therefore, efforts are currently underway
to integrate the pathologic evaluation with molecular features to get a more
comprehensive description of a particular tumor (8). This has led to several
research groups focusing on molecular data to identify tumor subtypes within MIBC
in order to quickly identify the patients who are most at risk, or to identify those who
would most likely respond to the available treatment options.
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1.2.

Molecular Subtyping

In 2000, Perou and colleagues realized that breast tumors exhibited different
molecular properties affecting their responsiveness to treatments (9, 10). In order to
understand the diversity of breast cancers, they characterized the gene expression
patterns from 42 unique breast cancers and sought to identify molecular subtypes.
They used microarrays that measured the expression of 8,102 genes to study the
gene expression patterns, and performed hierarchical clustering to group the
samples. They found that the molecular portraits obtained pointed towards useful
biological interpretations, such as signaling pathways. They identified 5 intrinsic
subtypes of breast cancer that were related to different molecular features: basallike, ERBB2+, normal breast-like, luminal A, and luminal B. They note a distinct
difference between the two luminal subtypes, which are estrogen receptor (ER)
positive, and the basal-like and ERBB2+ subtypes, which are ER negative, and the
importance to treat these two subtypes as distinct diseases.
This was the first study that explored the heterogeneity within a specific cancer
type, and indicated that cancers of a particular organ are clinically distinct. By
identifying subtype membership, clinicians are able to identify potential treatment
strategies that will work best. By using breast cancer as a model, similar
approaches have been taken to identify molecular subtypes of MIBC in order to
better understand the molecular heterogeneity within the disease.
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1.2.1. M.D. Anderson (MDA) oneNN classifier
Using the work done to identify intrinsic subtypes of breast cancer as a model,
Choi and colleagues at MDA performed whole genome messenger RNA (mRNA)
expression profiling on a cohort of 73 fresh-frozen primary MIBCs. They used
Illumina BeadArrays to assess the expression of over 48,000 mRNAs, performed
unsupervised hierarchical clustering, and identified three molecular subtypes of
MIBC. These three subtypes are referred to as: basal, p53-like, and luminal, which
were validated in an independent cohort of formalin-fixed paraffin embedded MIBCs
(11).
The basal subtype showed enrichment of genes associated with basal breast
cancers and squamous features (11). The basal subtype was also characterized as
being more aggressive, often having metastatic disease at presentation, and shorter
disease-specific and overall survival rates (11). Basal MIBCs, similar to basal breast
cancers, expressed high molecular weight cytokeratins (KRT5, KRT6A/B/C, KRT14)
and mesenchymal markers (ZEB2, VIM, TWIST1/2). Ingenuity Pathway Analysis of
upstream regulators predicted STAT3, HIF1α, and TP63 to be transcriptional
regulators of basal gene expression.
The luminal subtype of MIBC expressed the epithelial marker E-cadherin and
canonical luminal biomarkers FOXA1, GATA3, ERBB2 and KRT20. Luminal MIBCs
were enriched for fibroblast growth factor receptor 3 (FGFR3) mRNA expression and
FGFR3 activating mutations, which are common features of NMIBCs. Ingenuity
Pathway Analysis of upstream regulators implicated peroxisome proliferatoractivated receptor, gamma (PPARG), ER and TRIM24 in the transcriptional
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regulation of luminal MIBC. Luminal MIBCs had PPARG activation, active PPAR
pathway, high PPARG mRNA expression, and high expression of PPARG’s direct
target and coactivator, fatty acid binding protein 4 (FABP4). Overall, when
compared to the basal subtype, the luminal tumors had significantly better overall
and disease-specific survival.
The p53-like subtype identified was primarily characterized by expression of an
active p53 signature, but also expressed luminal biomarkers. Silhouette scores
were calculated, which is a measure of subtype stability, and showed that the p53like subtype was rather unstable, with 35% of the tumors calculated to be unstable.
Despite having expression of luminal biomarkers, the p53-like tumors showed
significantly poor overall and disease-specific survival when compared to the luminal
tumors. Subsequent in vitro analyses found that these MIBCs were significantly
resistant to neoadjuvant cisplatin-based chemotherapy when compared to the other
subtypes.

1.2.2. UNC BASE47 subtype classifier
Damrauer and colleagues at UNC also sought to identify molecular subtypes of
MIBC. They compiled samples from 3 different experiments and generated a metadataset of 262 MIBCs. Using whole genome expression profiling, and unsupervised
consensus clustering, they identified 2 intrinsic subtypes of MIBC termed basal-like
and luminal (7). Similar to results in breast cancer, and from MIBC studies at MDA,
the basal-like and luminal subtypes exhibited significantly different clinical outcomes,
with the basal-like subtype showing poorer outcomes. As a result of their analyses,
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they developed a prediction analysis of microarrays (PAM) classifier, termed bladder
cancer analysis of subtypes by expression (BASE47), which consisted of 47 genes
that could accurately identify basal-like and luminal MIBCs.
They studied the genes that were significantly differentially expressed between
the two clusters and identified 2,393 genes. Similar to previous findings, the basallike subtype expressed high molecular weight cytokeratins (KRT5, KRT6B, KRT14)
and CD44, while the luminal subtype expressed KRT20. The basal subtype also
exhibited enrichment of genes involved in cell survival and movement.
In their study, they also emphasized the similarity of the basal-like MIBC subtype
to the basal-like breast cancer subtype, and luminal MIBC to luminal breast cancer.
They correlated the centroid gene expression between the bladder and breast
cancer subtypes, and identified positive correlation between basal-like MIBC and
basal-like and normal-like breast cancers, while luminal MIBC showed positive
correlation with the luminal A and luminal B breast cancer subtypes (7). They also
showed that 16% of the MIBCs shared similar characteristics to the claudin-low
molecular subtype of breast cancer, which is characterized by low expression of
claudins and increased expression of mesenchymal markers (7). While all of these
claudin-low tumors were within the basal-like subtype, they did not show differences
in clinical outcomes when compared to the rest of the basal-like tumors.

1.2.3. The Cancer Genome Atlas (TCGA)
TCGA also performed their own analysis to identify subsets of MIBC using RNA
sequencing, and identified four expression subtypes. They used 129 chemotherapy-

9

naive, muscle-invasive urothelial carcinomas and performed mRNA, miRNA, and
protein expression analyses (4).
Their Cluster I tumors were enriched for papillary morphology, FGFR3 mutations,
FGFR3 copy number gain and elevated FGFR3 expression, suggesting that this
subtype may respond to FGFR inhibitors. Cluster I and Cluster II expressed high
levels of ERBB2 and ESR2 proteins, and showed similar features of Luminal A
breast cancer, with expression of GATA3, FOXA1, and E-cadherin. Cluster III,
basal/squamous-like, expressed high molecular weight cytokeratins (KRT5, KRT6,
KRT14) and showed similarity to basal-like breast cancers and squamous cell
cancers of the head, neck and lung (4). The Cluster IV tumors had low expression of
luminal markers, moderate expression of basal markers, and relatively high
expression of miR-99a and miR-100.

1.2.4. Lund subtype classification
Another group at Lund University also sought to develop a method to classify
tumors based on molecular features. They used 308 bladder cancer cases, and
identified 5 major subtypes: urobasal A (UroA), genomically unstable (GU), urobasal
B (UroB), squamous cell carcinoma-like (SCCL), and infiltrated (Infil) (8). They
performed hierarchical clustering with 308 tumor samples and used a successive
two group split approach to identify their clusters. The first split identified two
subtypes, which were treated individually to establish further divisions, resulting in
the identification of 7 distinct subsets (8).
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The UroA subtype was characterized by FGFR3 mutations, FGFR3 mRNA
expression, and expression of an FGFR3 gene signature. A majority of these
tumors were NMIBC, contributing to their overall good prognosis. The GU subtype
was characterized by TP53 mutations, increased activity of late cell cycle genes, and
expression of KRT20. Approximately 70% of the GU tumors were pathologically
described as being high grade. The SCCL subtype expressed high molecular
weight cytokeratins (KRT6A/B/C, KRT14), was associated with poor prognosis, and
showed pathologic signs of squamous cell differentiation. Similar to the UroA
subtype, the UroB subtype had high frequency of FGFR3 mutations, but also
expressed high molecular weight cytokeratins like the SCCL subtype. It was
suggested that the UroB tumors may be a progressed state of UroA tumors. The
Infil subtype had a strong immunologic signal, suggesting the presence of
myofibroblasts, but the subtype showed quite a bit of heterogeneity because it had
protein expression signatures similar to GU, UroB, and SCCL tumors.
Overall, they confirmed that the identification of molecular subtype could predict
overall prognosis, with UroA showing good prognosis, GU and Infil showing
intermediate prognosis, and UroB and SCCL showing the worst overall survival
outcomes.

1.2.5. Summary of subtype classifications
Four different studies identifying molecular subtypes of urothelial carcinomas are
highlighted here. Each group used different platforms to acquire whole genome
expression data, different patient cohorts, and different methods to analyze the data.
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Despite these differences, there is a remarkable amount of similarity between all of
the classifiers.
Using TCGA’s latest RNA-sequencing MIBC cohort (n=408) and subtype calls on
this cohort from the above studies, we see that the data generally fall into two
subtypes, basal and luminal (Figure 2). The MDA identified basal tumors overlap
substantially with the SCCL tumors identified by Lund, and encompass all of TCGA’s
Cluster III and most of the Cluster IV tumors. The basal-like tumors identified by
BASE47 encompass these subtypes, but also includes approximately half of the
MDA p53-like tumors, and half of TCGA’s Cluster II tumors. The MDA identified
luminal tumors overlap with the UroA and GU tumors identified by Lund, and
encompass TCGA’s Cluster I and some of the Cluster II tumors. The BASE47
luminal subtype encompasses MDA’s luminal tumors, half of MDA’s p53-like tumors,
Lund’s GU, UroA, and a small portion of the Infil subtype. The tumors identified as
p53-like by MDA encompass TCGA’s cluster II and Lund’s GU, UroA and Infil
subtypes.
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Figure 2: Summary of different subtype classifications. Using TCGA’s cohort of
408 tumors we compared subtype identifications from the four different groups.
UNC’s 2 cluster solution: basal-like (red), luminal (blue); MDA’s 3 cluster solution:
basal (red), luminal (blue), p53-like (green); Lund’s 5 cluster solution: GU (purple),
Infil (green), SCCL (red), UroA (blue), UroB (yellow); TCGA’s 4 cluster solution:
cluster I (blue), cluster II (green), cluster III (red), cluster IV (yellow), missing
information (gray).
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1.3.

Non-coding RNAs (ncRNAs)

The current understanding of the human genome is that the majority of our
genome is transcribed but does not encode for protein. These portions of our
genome were previously thought to be junk in the genome. However, recently this
“junk” has become of major interest with the hypothesis that the non-coding regions
of our genome are important and provide a hidden layer of signals that are
controlling various levels of gene expression. There are many different classes of
non-coding RNAs, including but not limited to transfer RNAs (tRNAs), ribosomal
RNAs (rRNA), small nucleolar RNAs (snoRNAs), long non-coding RNAs (lncRNAs),
and micro-RNAs (miRNAs).
Non-coding RNAs have become of prime interest in studying the heterogeneity of
disease, because of their usefulness in making clinical predictions of outcome.
While whole genome expression profiling data based on mRNA expression has
become particularly useful to identify molecular tumor subtype, which has the
potential to predict prognosis and response to treatment, this has not been easily
translated into routine clinical practice worldwide mostly due to economic and
technical reasons. Therefore, ncRNAs are primed to be used as potential
biomarkers in minimally invasive clinical tests, as they have been shown to predict
the presence of disease with high sensitivity and specificity. In this work, two
classes of ncRNAs are explored, lncRNAs and miRNAs, because of their aberrant
expression in several cancer types and their accessibility and stable expression in
bodily fluids (12).
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1.3.1. Micro-RNAs (miRNAs)
There are currently 1,881 annotated human miRNAs, according to miRbase
version 21. MiRNAs are estimated to regulate approximately 30% of all human
genes, with one single miRNA having the ability to affect up to 200 different mRNA
targets (13). Due to the number of potential mRNA targets, miRNAs have been
suggested to exert tissue-specific functions as they often target different mRNAs in
different tissues. MiRNAs are small, single stranded RNAs with an approximate
length of 22 nucleotides (nts). They have been described as critical for a wide range
of biological processes because of their regulation of gene expression at a posttranscriptional level. In breast cancer, it has been suggested that miRNA detection
in bodily fluids is far superior to mRNA profiling because of their high tissuespecificity and stability. The addition of miRNA expression to current molecular
classifications may add robustness, and improve diagnosis and treatment of multiple
disease types (12).
MiRNAs were first discovered in 1993 with the identification of Lin-4 in the
nematode C. elegans (14). Several years later, in 2000, the miRNA let-7 was
identified in C. elegans (15) and was shown to have sequence conservation in
humans (16). The miRNA let-7 was detected in various human tissues and was
shown to consist of 12 distinct human miRNAs within the let-7 family (15, 17). The
finding that let-7 was conserved across species led to a change in the research field,
and initiated research efforts focused on understanding small ncRNAs.
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1.3.1.1.

miRNA function

MiRNAs were found to regulate gene expression by targeting mRNAs through
sequence specific targeting, resulting in mRNA degradation or translational
repression. The recognition of the target mRNA is based on the complementarity of
seven to eight nucleotides at the 5’-end of the miRNA (seed sequence) to the
specific motif along the 3’-untranslated sequence of the target mRNA (13). Perfect,
or nearly perfect, complementarity can induce degradation of the mRNA, while
imperfect base pairing can result in translational inhibition (13). Translational
repression occurs more frequently and is mediated by blocking the initiation step
therefore affecting mRNA stability (18). MiRNAs have also been described as having
decoy abilities, which is a less studied mechanism. In a decoy state, the miRNA
would interfere with the function of proteins by preventing interaction between
coordinating mRNAs (19).

1.3.1.2.

miRNAs and cancer

The dysregulation of miRNAs in cancer was first reported in 2002, with the
discovery of miR-15 and miR-16 being frequently deleted in chronic lymphocytic
leukemia (CLL) (20). Since this discovery was made there have been several
studies showing differential miRNA expression profiles in tumor versus normal
tissues (21, 22).
MiRNAs have even been implicated in the initiation and progression of many
cancers, suggesting that they play a key role in cancer biology (23). Several studies
have also shown that the overexpression of a single miRNA is sufficient to initiate
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tumor development (24, 25). Deregulated miRNAs can also influence tumorigenesis
by decreasing or increasing the inhibition of their mRNA targets, which has led to the
identification of oncogenic miRNAs and tumor suppressive miRNAs (13, 26).
Oncogenic miRNAs are often upregulated in tumor tissues and target tumor
suppressor genes, while tumor suppressive miRNAs are frequently downregulated in
cancer and target oncogenes. However, subsequent studies have shown that
miRNAs are more complex and may have dual functions depending on tumor type or
stage in progression. Also, since miRNAs bind to their targets with partial, rather
than perfect complementarity, there are multiple challenges with identifying mRNA
targets in silico.
While miRNAs are thought to act on downstream signaling, they are often
involved in feedback loops, causing the expression of miRNA families to be
regulated by transcription factors (27, 28). MiRNA expression can also be regulated
by epigenetic modifications, as demonstrated by miRNA expression changes after
exposing cells to DNA methylation inhibitors and histone deacetylase inhibitors (29,
30). While epigenetic modifications can control miRNAs, miRNAs have also been
implicated in controlling epigenetic changes.
In cancer, miRNAs have been shown to play an important role in controlling
metastasis, which is one of the primary causes of cancer-related deaths. There are
multiple steps involved in the metastatic process, in which miRNAs can either
promote or inhibit metastasis (31). For example, miRNA-10b has been shown to
positively regulate migration and invasion, and is capable of initiating metastasis in
mice by targeting repressors of metastasis (32). However, more miRNAs have been
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implicated in metastasis suppression, including miR-335, miR-126, miR-206, and the
miR-200 family, by targeting transcription factors involved in metastasis initiation
(ZEB1/2, TWIST, VIM, FN1) (33, 34).

1.3.1.3.

miRNAs and bladder cancer

The first indication that miRNAs were deregulated in bladder cancer occurred in
2007, with the identification of 10 distinct miRNAs that were up-regulated in bladder
cancers when compared to normal tissues (35). This study identified miR-223, miR26b, miR-221, miR-103-1, miR-185, miR-23b, miR-203, miR-17-5p, miR-23a, and
miR-205 to be significantly overexpressed in bladder tumors (35). Since this initial
discovery, several large-scale experiments have identified differences in miRNA
expression patterns across the different stages and grades of bladder cancer. Lowgrade bladder cancers have been shown to have downregulation of several
miRNAs, while high-grade bladder cancers are often associated with upregulation of
miRNAs (36, 37). In low-grade bladder cancers, there is downregulation of miR-145,
miR-143, miR-99a, and miR-100, which upregulates expression of FGFR3 (Figure 3)
(36-38). In high-grade bladder cancers, there is downregulation of miR-145 to inhibit
apoptosis, and upregulation of miR-21 to inhibit the p53 pathway (Figure 3) (39).
Very few differences in miRNA expression were previously identified between highgrade NMIBC and MIBC.
While studies have identified differences in miRNA expression between NMIBC
and MIBC, the reproducibility of these miRNA expression signatures has not been
possible due to the heterogeneity of tumor specimens and research methods. The
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majority of miRNA studies to date in bladder cancer consist of profiling experiments
to compare miRNA expression profiles in normal bladder versus NMIBC or MIBC
(40). While this is a good start, we have barely scratched the surface of the miRNAs
involved in bladder cancer development, progression, and the intrinsic molecular
subtypes that are present in MIBC.
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Figure 3: miRNAs identified in low-grade and high-grade bladder cancers.
(Left) As normal urothelium progresses into low grade bladder cancer there are
several changes in miRNA expression. The miRNAs in the green box are
downregulated, and the miRNA in the red box is upregulated in low grade bladder
cancers. This miRNA expression pattern has been shown to induce FGFR3
expression. (Right) The miRNAs involved in high grade bladder cancers are distinct
from the miRNAs identified in low grade tumors. The miRNA expression patterns in
high grade bladder cancers are implicated in inhibition of apoptosis and the p53
pathway, and induction of EMT and proliferation.

20

1.3.1.4.

miRNAs as biomarkers

MiRNAs have been implicated in identifying subtypes of breast cancer since
miRNA expression levels were shown to predict ER, progesterone receptor (PR) and
ERBB2 receptor status in breast cancer, suggesting that miRNAs might differentiate
between basal and luminal subtypes (41). MiRNAs have also been associated with
metastasis and epithelial-mesenchymal transition (EMT), suggesting that these
miRNAs might serve as valuable biomarkers to predict metastasis and tumor
recurrence.
Since cancers are commonly diagnosed through invasive techniques that involve
taking a biopsy of the tumor tissue, miRNAs have been explored as potential
biomarkers in bodily fluids. In cancer, the first experiment using miRNA expression
profiles from the blood serum of patients was performed, and identified differences in
the expression levels of three different miRNAs (42). Given the potential of miRNAs
to differentiate between cancer subtypes, there is a possibility that non-invasive
techniques based on miRNA expression could not only diagnose cancer, but also
identify tumor subtype or patients that have a high propensity to develop recurrence.
There have been a few studies that assessed the possibility of using urine from
bladder cancer patients to identify miRNA biomarkers, revealing the stability of
urinary miRNAs and the potential to use them in future diagnostic assays.
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1.3.2. Long non-coding RNAs (lncRNAs)
The first suggestion that not all long RNA transcripts were protein-coding came
with the identification of H19, a paternally imprinted maternally expressed transcript
that is often deregulated in tumors (43, 44). This led to the subsequent identification
of other lncRNAs, such as X inactive specific transcript (XIST) (45), and growth
arrest-specific 5 (GAS5) (46).
There are currently over 21,000 identified lncRNAs, but there are likely more that
have not yet been discovered since 15% of the genome remains unannotated and
lncRNAs overlapping with protein-coding regions have not been analyzed yet (47).
LncRNAs are arbitrarily defined as a class of non-coding RNAs that are longer than
200 nts in length, and have been implicated in a variety of biological functions by
regulating the expression of genes involved in cell cycle progression, apoptosis and
differentiation (47). While lncRNAs are implicated as biological signal transducers,
the molecular mechanisms by which lncRNAs function still need to be elucidated.
Due to the lack of knowledge surrounding the functions of the identified lncRNAs,
lncRNAs are primarily characterized based on their position relative to proteincoding genes. Intergenic lncRNAs are the most commonly identified class of
lncRNA, but lncRNAs can also be transcribed from exons, introns or overlapping
regions of protein-coding genes (48).
LncRNAs share similar length and processing to that of protein-coding genes.
While lncRNA sequences are not well conserved across species, they do exhibit
tissue-specific expression but are expressed at a lower level when compared to
protein-coding genes (49).
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1.3.2.1.

LncRNA mechanisms

While only a handful of lncRNAs have been well characterized to date, they have
been shown to control every level of gene expression. They have been implicated in
transcriptional gene silencing through chromatin structure, and posttranscriptional
gene regulation by controlling protein synthesis and RNA transport (49, 50). In
addition, many lncRNAs are thought to reside in the nucleus where they can actively
regulate gene expression through chromatin remodeling complexes or potentially
interact with the DNA itself (47). However, the physical association between lncRNA
and chromatin modifier or gene promoter are still unclear.
LncRNAs appear to have a wide range of molecular functions, but they most
likely act as a “scaffold” to assist and support the assembly of RNA-protein
complexes (48). LncRNAs have also been suggested to act as guides, where they
assist in the recruitment of RNA-protein complexes to target genes (48). LncRNAs
may also act as a decoy by binding proteins and inhibiting the interaction between
the sequestered protein and downstream target (48). While lncRNAs are primarily
implicated in downstream signaling, they may also play a role upstream to control
transcription factors. Overall, the mechanisms of lncRNAs are still being explored.

1.3.2.2.

LncRNAs and cancer

Some of the first lncRNAs identified have been shown to be deregulated in
human tumors when compared to normal controls, including H19 as a potential
oncogene (43, 51-55) and GAS5 as a potential tumor suppressor (56, 57). The idea
that lncRNAs exhibit cancer-specific expression was further strengthened by the
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discovery of the prostate cancer antigen 3 (PCA3) lncRNA (58). It was found to be
specifically overexpressed in malignant prostate tissue, and was further developed
into a diagnostic tool (59). Subsequently, lncRNAs have been described in major
pathways involved in cancer formation and progression.
To date, several studies have focused on the differential expression of lncRNAs
in normal versus cancerous tissue, and have identified several lncRNA biomarkers
associated with grade, lymph node metastasis and subtype classification (60).
Overall, alterations in lncRNA expression have been associated with tumor
formation, progression and metastasis by regulating gene expression involved in
associated pathways.

1.3.2.3.

LncRNAs and bladder cancer

There have been 6 lncRNAs that have been implicated in bladder cancer, which
are summarized in Table 1. The lncRNA H19 has been found to promote metastasis
by inhibiting E-cadherin, which results in the indirect activation of pathways that
promote EMT (53). H19 was also shown to increase bladder cancer growth by
directly inducing the MYC transcription factor (61).
The metastasis associated lung adenocarcinoma transcript (MALAT1) lncRNA
was shown to be significantly overexpressed in bladder cancers. Overexpression led
to increased cell proliferation and EMT activation (62). Taurine upregulated gene 1
(TUG1) was also identified as overexpressed in bladder cancers, and was
significantly associated with high-grade tumors (63). When MALAT1 and TUG1
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interact, they have been shown to regulate genes involved in growth control
processes.
Urothelial cancer associated 1 (UCA1) is one of the most well studied lncRNAs
involved in bladder cancer. It is considered to be an oncogene since it is
overexpressed in bladder cancers. Overexpression of UCA1 was shown to enhance
key signaling cascades involved in cell cycle, carcinogenesis and invasion (64-66).
There are three identified isoforms of UCA1, one of which was associated with
cisplatin resistance and promoting tumorigenicity (67).
The maternally expressed 3 (MEG3) lncRNA has also been identified in bladder
cancers, where it is considered to act as a tumor suppressor by activating p53 via
MDM2 inhibition (68). MEG3 expression levels were shown to be significantly
reduced in bladder cancers compared to normal controls (69), which led to
increased cellular proliferation and autophagy activation (70).
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LncRNAs identified in Bladder Cancer vs. Normal Controls
LncRNA

Function

Evidence

H19

Oncogene

Targets E-cadherin, induces EMT

MALAT1

Oncogene

Induces cell proliferation, migration,
EMT through WNT signaling

SNHG16

Oncogene

Positive association with chemoresistance and aggressive disease

TUG1

Oncogene

UCA1

Oncogene

MEG3

Tumor suppressor

Associated with high-grade tumors
and stage
Promotes cell cycle, progression,
and invasion
Activates p53, inhibits autophagy
and proliferation

Table 1: LncRNAs identified to have oncogenic or tumor suppressive roles in
bladder cancer. LncRNAs previously identified in bladder cancer versus normal
controls, and their associated role as an oncogene or tumor suppressor.
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1.3.2.4.

LncRNAs as biomarkers

The altered expression of lncRNAs in urologic cancers, and their demonstrated
involvement in cancer associated cellular processes, present them as attractive noninvasive biomarker candidates. This opens up the possibility for the development of
clinical diagnostic tools, and possibly novel therapeutic strategies.
LncRNAs have become of interest because of their detection in bodily fluids, and
their potential use as diagnostic or prognostic biomarkers. For example, HOX
transcription antisense RNA (HOTAIR) was one of the first lncRNAs identified, and it
was found to be associated with invasion and metastasis in breast cancers (12). The
first lncRNA that was approved as a diagnostic urinary biomarker was PCA3
expression in prostate cancer (59). In bladder cancers, UCA1 expression has been
measured in urine sediments, resulting in a sensitive and specific diagnostic tool to
identify bladder cancer (71).
Since lncRNAs are expressed in a highly tissue, disease, or developmentalspecific manner, they could serve as highly specific diagnostic, prognostic, or
predictive biomarkers. With the rising number of newly discovered lncRNAs, and the
accumulating evidence elucidating their functionality, there is promise for their future
use in clinical practice.

1.3.3. ncRNA summary
The conventional understanding of gene regulation in biology has centered
around protein-coding genes. However, over several years, evidence has
suggested that the evolution and development of processes regulating the
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complexity of the genome is mainly due to the regulatory potential of the noncoding
portions of the genome (47). Only approximately 1.5% of the genome is protein
coding, while the non-coding regulatory elements are transcribed into non-coding
RNA, simply indicating that ncRNAs could play a significant regulatory role in
complex organisms. While miRNAs are highly conserved across species and
involved in transcriptional and posttranscriptional gene silencing through specific
base pairing with their targets, lncRNAs are defined as transcribed RNA molecules
greater than 200 nt in length that are poorly conserved across species and regulate
gene expression by diverse mechanisms that are not yet fully understood (72).

1.4.

Rationale
Overall, miRNAs are emerging as promising biomarkers for diagnosis,

prognosis and response to therapy. MiRNAs are easily accessible, affordable, and
present the opportunity for the development of non-invasive tools for personalized
therapy. The accurate and convenient diagnosis for urologic cancers remains
clinically challenging, therefore the biggest advantage to using miRNAs is that they
are released from the tumor tissue in the plasma or urine where they can be easily
collected and analyzed. Understanding the biology of bladder cancer progression
and metastasis, as well as identifying critical markers of survival, is very important
for the long-term purpose of discovering a cure for this disease. Given the role that
non-coding RNAs may play in controlling the transcriptional regulation of the intrinsic
subtypes of MIBC, we initiated the present study to explore the role of non-coding
RNAs in the intrinsic subtypes.
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Materials and Methods
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2. Materials and Methods

Contents of this chapter are based on Ochoa AE, Choi W, Su X, Siefker-Radtke A,
Czerniak B, Dinney C, McConkey DJ. 2016. Specific micro-RNA expression
patterns distinguish the basal and luminal subtypes of muscle-invasive bladder
cancer. Oncotarget 7(49):80164-80174.
Copyright permission not required since Oncotarget journal policy states that,
“authors retain ownership of the copyright for their article.”

2.1. Methods for Chapter 3
2.1.1. Human Specimens
Informed consent was obtained from all patients who contributed tumors to
the TCGA and MD Anderson bladder cancer cohorts utilized in this study. All of the
genomics studies were performed in compliance with US guidelines under approved
IRB laboratory protocols.

2.1.2. Validation Cohort
62 fresh frozen (FF) patient samples were previously analyzed by Illumina
HTv3 BeadChip microarray (11). The messenger RNA expression data was
downloaded from GEO, dataset GSE48075. The dataset was quantile normalized
and log2-transformed. Subsequent differential expression was performed using the
R Bioconductor package, linear models for microarray data (limma) (73).
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2.1.3. Ion Torrent small RNA sequencing
The same 62 RNA samples were used to perform small RNA sequencing on
the Ion Proton. First, the percentage of small RNA within the total RNA sample was
quantified using Small RNA and RNA 6000 Nano bioanalyzer chips from Agilent.
After calculating the percentage of small RNA in the total RNA sample, we
calculated the quantity required to reach 20 nanograms (ng) of small RNA, which
was used for library preparation using the Ion Total RNA Seq v2 library preparation
kit. The small RNA library was constructed by hybridizing and ligating the RNA,
followed by reverse transcription to yield cDNA. The cDNA was then purified, sizeselected, and barcoded. The resulting cDNA library was quantified with High
Sensitivity DNA bioanalyzer chips from Agilent to determine the molar concentration
of each library, and to calculate the percentage of library that is barcoded small
RNAs. The cDNA libraries were then diluted to the same molar concentration,
pooled, and diluted to 100 picomolar (pM). The pooled sample was then templated
and sequenced with the Ion Proton. The GEO accession number for the small RNA
sequencing data presented in this study is GSE84525.

2.1.4. TCGA training data set
Bladder cancer RNA and miRNA-sequencing level 3 data was extracted from
the TCGA data portal. TCGA normalized RNAseq (RSEM) and miRNA-seq counts
(RPM – reads per million mapped miRNA) were log2-transformed, median centered
and filtered based on a fold change of or greater than 2 in at least 10% of the
samples.
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2.1.5. Consensus Clustering
Messenger RNAs and miRNAs that passed the filtering criteria were used for
hierarchical consensus clustering (CC) in the R package ConsensusClusterPlus,
with 80% resampling and 1,000 iterations (74). Read counts for both mRNAs and
miRNAs were used as input for differential expression analysis in the R package,
edgeR (75, 76). All analyses utilized a false-discovery rate (FDR) cutoff of 5%, and
a fold change cutoff of 2.

2.1.6. Subtype Prediction
Prediction analysis of microarrays (PAM) was used to identify the minimal
number of mRNAs or miRNAs that could accurately predict subtype classification
using TCGA’s cohort and the mRNA CC (k=2) calls as a reference (77). The
analysis resulted in a 593-mRNA predictor (Δ = 6.969), and a 63-miRNA predictor (Δ
= 3.898), which was validated using the 62 FF cohort.

2.1.7. Identification of downstream targets
Potential downstream target mRNAs of the differentially expressed miRNAs
were analyzed using Ingenuity Pathway Analysis miRNA target filter. In order to be
considered as an mRNA target, the mRNA and miRNA had to be negatively
correlated.
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2.1.8. Survival Analyses
Clinical data for TCGA’s cohort was extracted from TCGA’s data portal, and
survival curves were generated in GraphPad Prism 6.

2.2. Methods for Chapter 4
2.2.1. TCGA data
Raw bladder cancer RNA-seq data (BAM files) and their related clinical data
were downloaded from the Cancer Genomics Hub (CGHub) and TCGA data portal.
The BAM files were converted to paired-end FASTQ files for each sample using
bam2fastq. The raw paired-end reads in FASTQ format were aligned to the human
reference genome, GRCh37/hg19, using MOSAIK and saved as BAM files (78).
Raw counts for each gene were then generated by counting the mapped reads in
mRNAs and lncRNAs annotated in GENCODE15 using the HTSeq package. We
used the “union” mode in HTSeq to mask the overlapped regions between mRNA
and lncRNA to overcome the issue of non-strand specific RNA sequencing in
TCGA’s data. Raw read count data were normalized using DESeq (79). Messenger
RNAs and lncRNAs were kept for subsequent analysis if their FPKM was equal to or
above 1 in at least 10% of the samples.

2.2.2. Differential expression analysis
Differentially expressed mRNAs and lncRNAs were identified using DESeq in
the R statistical programming environment (79). Significantly differentially expressed
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mRNAs and lncRNAs were identified using an FDR cutoff of or less than 5%, and
fold change cutoff of or more than a 2-fold difference.

2.2.3. LncRNA Consensus Clustering
Consensus hierarchical clustering was performed with 500 runs and 80%
resampling using the lncRNA expression data.

34

Chapter 3: Results
miRNA expression profiles identify subtypes of MIBC
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Chapter 3: miRNA expression profiles identify subtypes of MIBC

Contents of this chapter are based on Ochoa AE, Choi W, Su X, Siefker-Radtke A,
Czerniak B, Dinney C, McConkey DJ. 2016. Specific micro-RNA expression
patterns distinguish the basal and luminal subtypes of muscle-invasive bladder
cancer. Oncotarget 7(49):80164-80174.
Copyright permission not required since Oncotarget journal policy states that,
“authors retain ownership of the copyright for their article.”

3.1. Introduction and Rationale
MIBC is a highly heterogeneous disease where approximately half of the patients
respond to treatment, while the other half does not. Recently, anti-PDL1 immune
checkpoint inhibitor was approved for MIBC (5, 6), providing patients with an
alternative treatment option. While prognostication is based entirely on clinical and
pathological criteria, several large-scale genomics projects have provided new
insights into the molecular heterogeneity of MIBC. The subtypes of MIBC that have
been identified have shown similarities to the intrinsic molecular subtypes of breast
cancers (4, 7, 8, 11). The “basal” (or “squamous cell like”) subtype (80) is enriched
with squamous histopathological features, and is often associated with advanced
and metastatic disease at presentation along with shorter survival outcomes (4, 8,
11). The “luminal” (or “papillary”) subtype had overall better outcomes, are enriched
with papillary histopathological features and activating FGFR mutations (4, 8, 11,
81). Since the basal and luminal subtypes of MIBC display distinct biological and
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clinical differences, they should be treated differently. Unfortunately, there are no
reliable clinical tools that can quickly subtype MIBCs, revealing a true need in the
field.
One way to address the clinical need of a subtype identifier is to explore the
miRNA expression profiles of basal and luminal MIBCs. MiRNAs are attractive
cancer biomarkers because of their stability in body fluids and FFPE tissues (82,
83). Since miRNA expression has primarily been explored in the context of tumor
tissue versus normal tissue, we wondered whether miRNAs could also be used to
identify basal and luminal molecular subtypes of MIBC. In this chapter, we used
TCGA’s matched whole genome mRNA and miRNA expression data and generated
a new miRNA sequencing data set with 62 MIBCs from our own institution to explore
the miRNA expression profiles of basal and luminal cancers.

3.2. Results
3.2.1. Identification of MIBC subtypes
TCGA’s cohort is currently the largest, publicly available data set of high
quality whole transcriptome (mRNA and miRNA) MIBC data with 405 tumors. We
started with TCGA’s RNA-seq data. Using an unsupervised approach, we used
hierarchical consensus clustering (CC) to determine whether previous conclusions
about the molecular subtypes of bladder cancer were reproducible. CC identified a
three cluster (k=3) solution that best fit the data mathematically (Figure 4A), which
was consistent with our previous conclusions (11). The three CC clusters also
showed high expression of the biomarkers associated with the basal, p53-like and
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luminal subtypes previously identified (11). While there were similar expression
patterns, the CC subtype assignments were only 75% identical to the one-nearest
neighbor (oneNN) classifier subtype assignments (Figure 4B) (11). Most of the
discrepancies were due to class switches between the p53-like and luminal tumors,
which is consistent with previous conclusions (11). Even though a three-cluster
solution was mathematically optimal, the basal and luminal biomarker expression
was almost mutually exclusive in the infiltrated tumors (Figure 4C/D), suggesting that
a two-cluster (k=2) solution would be biologically accurate.
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Figure 4: mRNA consensus clustering 3-cluster solution. A. Unsupervised CC
with TCGA’s cohort (n=405) identified a 3-cluster solution to be optimal. B.
Comparison of the mRNA CC subtype assignments to MDA oneNN subtype
assignments (left), and to BASE47 assignments (right). C. Visualization of the
relative expression of MDA subtype biomarkers: basal biomarkers (top), luminal
biomarkers (middle), p53-like biomarkers (bottom). D. Visualization of the relative
expression of BASE47 genes: basal mRNAs (top), luminal mRNAs (bottom).
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Consistent with the idea of a k=2 solution being biologically accurate (Figure
5A), we observed excellent overlap (93%) with the subtype assignments made using
an independent basal/luminal PAM classifier (7). We also compared the
basal/luminal assignments made by CC to the basal/luminal assignments made by
oneNN, p53-like tumors were omitted, and observed 93% overlap (Figure 5B).
Visualization of the basal and luminal biomarkers confirmed excellent separation of
the basal and luminal CC subtypes. However, a small fraction of the basal tumors
that corresponded to some of the oneNN identified p53-like tumors, had noticeably
lower expression of both basal and luminal biomarkers (Figure 5C/D).
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Figure 5: mRNA consensus clustering 2-cluster solution. A. Unsupervised CC
with TCGA’s cohort (n=405) identified a 2-cluster solution. B. Comparison of the
mRNA CC subtype assignments to MDA oneNN subtype assignments (top), and to
BASE47 assignments (bottom). C. Visualization of the relative expression of MDA
subtype biomarkers: basal biomarkers (top), luminal biomarkers (bottom). D.
Visualization of the relative expression of BASE47 genes: basal mRNAs (top),
luminal mRNAs (bottom).
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3.2.2. mRNA PAM classifier development
We used the TCGA mRNA data set and the k=2 CC subtype assignment as a
training set, to develop our own mRNA PAM classifier. For validation, we used 62
samples from the MDA FF cohort (GSE48075, Table 2). Since the whole genome
expression profiling data was generated on two different platforms, we started with
12,407 mRNAs that passed the filtering criteria in TCGA’s cohort and were present
in the FF cohort to develop the PAM classifier. PAM identified 593 mRNAs that
optimally identified basal and luminal subtype classification, which contained 39 of
the 47 BASE47 genes (Figure 6A). There were a few discrepancies in the subtype
assignments made using this new PAM classifier and BASE47, which were largely
due to the presence of a small fraction of tumors that were double positive for basal
and luminal biomarkers (Figure 6).
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Characteristics of the MDA validation Cohort (n=62)

Cohort Size (n)
Mean Age (y) ± SD
Clinical Stage at Specimen Collection
(n)
cT2
cT3
cT4
Positive Clinical Lymph Nodes (n)
Positive Clinical Metastasis (n)
Median Overall Survival (m)

Total
62
68.7 ±
9.9

Basal
28 (45%)

Luminal
p-value
34 (55%)
67.9 ±
69.8 ± 10.3 9.6
0.686

38 (61%)
18 (29%)
6 (10%)
10 (16%)
5 (8%)
46.30

17 (61%)
9 (32%)
2 (7%)
5 (18%)
3 (11%)
18.70

21 (62%)
9 (26%)
4 (12%)
5 (15%)
2 (6%)
82.40

0.774

0.744
0.65
0.073

Table 2: Clinicopathologic characteristics of the MDA validation cohort (n=62).
Summary of the clinical characteristics of the validation cohort used. The MannWhitney U test was used to compare differences in mean age between groups. The
log-rank test was used to compare differences in survival between groups. Fisher’s
exact test was used to determine differences between groups for the remainder of
categorical variables.

43

Figure 6: 593-mRNA PAM genes. A. Visualization of the 593-mRNA PAM genes in
TCGA’s cohort. B. Visualization of the 593-mRNA PAM genes in the FF cohort.
Color bars: MDA – basal (red), luminal (blue), p53-like (green); BASE47 – basal
(red), luminal (blue); mRNACC/PAM – basal (red), luminal (blue).
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The 593 PAM mRNAs were then used to make subtype predictions on the 62
FF cohort (Figure 6B), resulting in 28 basal tumors and 34 luminal tumors. The 28
predicted basal tumors encompassed all the basal tumors originally identified by the
oneNN prediction, and had high expression of basal markers and basal BASE47
genes (Figure 7). The 34 predicted luminal tumors encompassed all the luminal
tumors identified by oneNN prediction and had high expression of luminal markers
and luminal BASE47 genes (Figure 7).
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Figure 7: mRNA PAM classifier identifies basal and luminal tumors in
validation cohort. A. Visualization of the relative expression of MDA basal and
luminal markers as a function of PAM identified subtype classification. B.
Visualization of the relative expression of BASE47 basal and luminal genes as a
function of PAM identified subtype classification. C. Comparison of mRNA PAM
subtype assignments and MDA oneNN assignments. Color bars: oneNN – basal
(red), luminal (blue), p53-like (green); PAM – basal (red), luminal (blue).
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3.2.3. Identification of miRNA based subtypes
After identifying the basal and luminal MIBCs in the two datasets, we
characterized their differential miRNA expression patterns as a step toward
identifying a miRNA-based signature that could distinguish the two subtypes. We
used the same unbiased approach, and used TCGA’s miRNA-seq data from 405
MIBCs to perform consensus hierarchical clustering (Figure 8). Using a k=2 solution
(Figure 8A), similar to the mRNA analyses, we observed 77% and 73% concordance
with the basal and luminal subtype assignments made by mRNA CC and BASE47,
respectively (Figure 8B). However, when we examined basal and luminal mRNA
biomarker expression based on the miRNA clusters, we observed a significant
fraction of the mRNA PAM-defined luminal tumors clustered with the miRNA-defined
basal cluster (Figure 8C/D).
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Figure 8: miRNA consensus clustering 2-cluster solution. Unsupervised CC
was performed with the miRNA expression from 405 tumors in TCGA’s cohort. A.
MiRNA CC identified 2 distinct clusters. B. Comparison of miRNA CC subtype
assignments to mRNA CC assignments (top), to BASE47 assignments (middle), and
to MDA oneNN assignments (bottom). C. Visualization of the relative expression of
MDA basal and luminal markers. D. Visualization of the BASE47 basal and luminal
genes. Color bars: miRNA CC – basal (purple), luminal (light blue); oneNN – basal
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(red), luminal (blue), p53-like (green); BASE47 – basal (red), luminal (blue);
mRNACC– basal (red), luminal (blue). Note: Orange boxes in C and D indicate
luminal tumors that are likely misclassified.

49

3.2.4. Developing a miRNA-based PAM classifier
Due to the number of misclassifications using an unbiased miRNA approach,
we concluded that a supervised approach based on the mRNA subtype calls would
generate more accurate information. Since there is only one publicly available
miRNA-seq data set with matched mRNA expression data, we needed to generate a
validation cohort. We generated a new miRNA-seq data set by performing small
RNA sequencing on 62 FF samples from MDA (11). Using TCGA’s cohort as a
training set, we used 412 miRNAs that passed filtering criteria in TCGA’s cohort and
were present in the FF cohort to develop a miRNA-based PAM classifier. PAM
identified 63 miRNAs that optimally assigned samples to the basal and luminal
subtypes identified by mRNA expression (Figure 9A/B).

50

Figure 9: miRNA PAM identifies basal and luminal tumors. A. Visualization of
the 63 miRNAs identified by PAM in TCGA’s cohort (n=405). B. Visualization of the
63 miRNAs identified by PAM in the FF validation cohort (n=62). Color bars: oneNN
– basal (red), luminal (blue), p53-like (green); BASE47 – basal (red), luminal (blue);
mRNACC – basal (red), luminal (blue); mRNA/miRNA PAM – basal (red), luminal
(blue).
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We confirmed that these 63 miRNAs could accurately distinguish basal and
luminal tumors using hierarchical clustering (Figure 10). This resulted in 85% and
83% concordance with the subtype assignments made by mRNA consensus
clustering and BASE47, respectively.
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Figure 10: Supervised hierarchical clustering with the 63 PAM miRNAs. A.
Hierarchical clustering was performed with the 63 PAM miRNAs in TCGA’s cohort,
and the relative expression of the 63 miRNAs is depicted in the heatmap. B.
Hierarchical clustering was performed with the 63 PAM miRNAs in the FF validation
cohort, and the relative expression of the 63 miRNAs is depicted in the heatmap.
Color bars: oneNN – basal (red), luminal (blue), p53-like (green); BASE47 – basal
(red), luminal (blue); mRNACC – basal (red), luminal (blue); mRNA/miRNA PAM –
basal (red), luminal (blue).
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3.2.5. miRNA expression patterns relate to basal/luminal biology
A survey of the results suggested that the known biological targets of the
miRNAs were relevant to basal and luminal biology. The basal tumors expressed
high levels of miR-155, miR-142, miR-221, miR-222, and miR-223, which are
miRNAs commonly associated with aggressiveness in other solid tumors and poor
prognosis (84-88). The luminal tumors expressed high levels of all the miR-200
family members (miR-200a/b/c, miR-141, miR-429), consistent with previous
findings in MIBC (4, 11). Members of the miR-200 family are known inhibitors of
EMT that directly target ZEB1 and ZEB2, core EMT transcription factors that directly
inhibit transcription of the epithelial adhesion molecule E-cadherin (34). Basal
tumors are known to express high levels of ZEB1/2, while the luminal tumors
express high levels of E-cadherin and low levels of ZEB1/2 (4, 11). These findings
are consistent with the idea that members of the miR-200 family play important roles
in controlling the biological properties of the basal and luminal subtypes of MIBC.

3.2.6. miRNA-mRNA relationships and relevance to bladder cancer biology
We used the Ingenuity Pathway Analysis miRNA target filter and miRTarBase
to identify additional miRNA-mRNA relationships that were either experimentally
observed or were highly predicted in the TargetScan database. The results revealed
that many of the basal subtype-associated miRNAs targeted mRNAs involved in
adipogenesis, differentiation and EMT suppression (Figure 11A). Specifically,
several basal miRNAs (miR-125b, miR-142, miR-143, miR-152, miR-155 and miR221/222/223) have been predicted to target genes involved in adipogenesis and
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RXR activation pathways (89-91). Most notably, miR-125b, miR-223, miR-99a and
miR-212 target FGFR2 and FGFR3, which are involved in luminal MIBC biology (4,
91-93). Several basal miRNAs (miR-125b, miR-142, miR-152, miR-146b, miR-222,
miR-212) have also been predicted to target luminal factors that have been
previously identified in breast cancer, including ERBB2, ERBB3, ERBB4 and FOXA1
(94-96). MiR-125b has also been predicted to inhibit homeobox (HOX) genes, which
control urothelial terminal differentiation and are highly expressed by luminal MIBCs
(97).
The miRNAs that were enriched in luminal MIBCs were predicted to target
pathways associated with invasion and metastasis, including EMT, fibrosis and the
actin cytoskeleton (Figure 11B). For example, experimentally observed targets of
miR-29c include 6 different collagens that are associated with fibrosis and possibly
support cancer-associated fibroblast infiltration (98, 99). MiR-10a, miR-20b and
miR-301 were also predicted to target STAT3, while miR-1287 and miR-191 were
predicted to target EGFR and IL6, respectively. EGFR and IL6 are upstream
regulators of STAT3, all of which have been implicated in basal breast and bladder
cancers (100, 101).
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Figure 11: Schematic representation of miRNA and mRNA target relationships.
A. MiRNAs overexpressed in basal tumors (indicated in red text) target luminal
genes (indicated in blue text) involved in differentiation, adipogenesis, and EMT
suppression pathways. B. MiRNAs overexpressed in luminal tumors (indicated in
blue text) target basal genes (indicated in red text) involved in EMT, fibrosis, actin
cytoskeleton, and basal gene expression pathways.
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3.2.7. Subsets of basal and luminal MIBC
It was evident from the beginning that a subpopulation of the basal tumors
expressed lower levels of both basal and luminal miRNAs, and this subpopulation
corresponded to p53-like tumors identified by the oneNN classifier. To explore this
heterogeneity further, we utilized the class assignments from the TCGA 3-cluster (k
= 3) mRNA CC solution to isolate the significant miRNAs and mRNAs that were
differentially expressed by the “infiltrated” CC (Figure 12). We identified 15 miRNAs
by differential expression analysis that were overexpressed by the “infiltrated”
cluster. We analyzed the basal and luminal subtypes separately, and performed
hierarchical clustering with the 15-miRNA signature. In the basal subtype, we
isolated 82% of the “infiltrated” tumors identified by mRNA CC (k=3), and in the
luminal subtype we isolated 83% of the “infiltrated” tumors (Figure 12A). The
“infiltrated” luminal tumors identified by the 15-miRNA signatures likely correspond to
TCGA’s cluster II, while the “infiltrated” basal tumors show similar expression
patterns to TCGA’s cluster IV (4).
We applied the 15-miRNA signatures identified in TCGA’s cohort to the 62 FF
cohort. The basal and luminal tumors as identified by mRNA PAM were analyzed
separately, and hierarchical clustering was performed with the 15-miRNA expression
signature (Figure 12B). In the basal subtype, all of the “infiltrated” tumors identified
by mRNA CC (k=3) and the oneNN p53-like tumors clustered together. In the
luminal subtype, 89% of the “infiltrated” tumors identified by CC were isolated by
hierarchical clustering. The 15-miRNA signature includes miR-133b, miR-133a,
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miR-143, miR-145, miR-99a and miR-100, which have been previously associated
with fibrosis and chemo-resistance (102-104).
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Figure 12: 15-miRNA signature identifies “infiltrated” subsets of the basal and
luminal subtypes. A. Hierarchical clustering was performed with the 15-miRNA
signature in TCGA’s cohort. The heatmaps depict relative expression of the 15miRNA signature. (Left) Basal tumors identified by mRNA CC were isolated and
subjected to supervised hierarchical clustering. (Right) Luminal tumors identified by
mRNA CC were isolated and subjected to supervised hierarchical clustering. B.
Hierarchical clustering was performed with the 15-miRNA signature in the FF
validation cohort. The heatmaps depict relative expression of the 15-miRNA
signature. (Left) Basal tumors identified by mRNA PAM were isolated and subjected
to supervised hierarchical clustering. (Right) Luminal tumors identified by mRNA
PAM were isolated and subjected to supervised hierarchical clustering. Color bars:
oneNN – basal (red), luminal (blue), p53-like (green); mRNACC3 – basal (red),
luminal (blue), “infiltrated” (green); mRNACC2 – basal (red), luminal (blue); PAM –
basal (red), luminal (blue).
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3.2.8. Survival outcomes
Lastly, we assessed the survival outcomes based on the subtype
assignments made using the 63 PAM miRNAs in TCGA’s cohort (n=405) to the
mRNA based subtype assignments. We compared the two-cluster solutions
(BASE47, mRNA CC, miRNA PAM), and we observed that in all cases patients with
basal tumors had the poorest clinical outcomes (Figure 13). Having clinically
available tests to prospectively identify patients with basal tumors is crucial, as our
previous work showed that basal MIBCs responded well to platinum-based
chemotherapy (11, 105).
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Figure 13: Survival analyses confirm that basal tumors have poor survival
outcomes. Survival analyses performed with TCGA’s cohort (n=405) confirm that
basal tumors identified by four different methods have poor survival outcomes. A.
Kaplan-Meier plot of overall survival based on MDA oneNN subtype assignments (p
= 0.0012). B. Kaplan-Meier plot of overall survival based on BASE47 subtype
assignments (p = 0.0021). C. Kaplan-Meier plot of overall survival based on mRNA
CC subtype assignments (p = 0.0012). D. Kaplan-Meier plot of overall survival
based on 63-miRNA signature assignments (p = 0.0014).
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3.3. Discussion
The first goal of this study was to confirm previous conclusions that had been
made regarding the intrinsic subtypes of MIBC (4, 7, 11). Using an unsupervised
approach and a high-quality RNA-seq data set, we were able to reproduce our
previous conclusion that a 3-subtype solution was mathematically optimal (11).
However, one of the subtypes that corresponded to our original p53-like subtype,
was unstable (11). Since there were stability issues, we concluded that a twosubtype solution corresponded better with the known biology. We used
unsupervised CC, and a k=2 solution, to develop a new mRNA PAM classifier. The
subtype identifications made by our new PAM classifier, were directly compared to
the assignments made by BASE47 and revealed over 90% concordance. We
concluded that the basal and luminal subtypes of MIBC are highly robust, and most
likely identify the intrinsic subtypes of bladder cancer.
The second part of this study was to develop a miRNA-based classifier that
could be used to assign tumors to the molecular subtypes of MIBC. Since miRNAs
are considerably more stable in body fluids, including urine and blood, the
development of a miRNA-based classifier present the possibility to perform tumor
subtype calls with non-invasive techniques or “liquid biopsies”. Also, miRNA
expression profiling presents a new opportunity in the assessment of FFPE tissue
sections, since the RNA isolated from these sections is often too degraded for
sequencing techniques. We used a supervised approach based on mRNA subtype
classifications to identify 63 miRNAs that assigned tumors to the basal and luminal
subtypes. Analysis of the 63 miRNAs suggested that they may serve as robust
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biomarkers, since their biological functions supported previous conclusions made
about the biology underlying the basal and luminal subtypes. Most of the
overexpressed basal miRNAs targeted mRNAs implicated in the control of luminal
biology (FOXA1, ERBB2), adipogenesis (FGFR2, FGFR3), and urothelial
differentiation (HOX genes), which are down-regulated in the basal subtype. The
miRNAs overexpressed in the luminal subtype targeted transcription factors that
control EMT (ZEB1/2), biomarkers associated with fibrosis and the actin
cytoskeleton (collagens), and basal cancer biology (IL6, EGFR, STAT3), which are
all suppressed in luminal cancers. Using the 63-miRNA signature, were able to
accurately assign MIBCs to the basal and luminal subtypes, and confirmed that the
basal tumors were associated with poor outcomes. We also identified a 15-miRNA
signature that identified sub-populations within the basal and luminal subtype that
appeared to be infiltrated with fibroblasts. This signature could prove to be useful in
identifying tumors that are resistant to traditional chemotherapy (11, 102, 106, 107),
but are sensitive to immune checkpoint blockade (6).
Overall, we identified high concordance between the calls made using
BASE47 and the new mRNA PAM classifier described here, demonstrating that
subtype identifications made using relative mRNA expression are highly robust. It is
becoming common practice to sequence the tumors of every single patient. Given
the number of currently available subtype classifiers, it should become common
clinical practice to subtype the tumors. However, this can be difficult when using
FFPE tissues, because of the variability in the quality of the RNA isolated. Often
times, samples are not usable because they do not pass standard quality control
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cut-offs. The identification of a miRNA-based classifier presents new opportunities
for subtype classification, since miRNAs are often stable in FFPE tissues and
degraded RNA samples. While the miRNA-based classifier does not appear to be
as robust as an mRNA-based classifier, it could be used as an alternative strategy
when samples do not pass quality checks. A miRNA-based classifier could also be
paired with an immunohistochemical classifier to confirm the subtype classifications
(108). Overall, the clinical identification of tumor subtype based on mRNA, miRNA,
or immunohistochemistry should become part of routine diagnostic practices for
MIBC in the near future.
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Chapter 4: Results
LncRNA expression subtypes in MIBC
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Chapter 4: LncRNA expression subtypes in MIBC

4.1. Introduction and Rationale
Our understanding of cancer biology has transformed recently with the latest,
large-scale cancer genomics projects that have been done. Recent studies in MIBC
have catalogued common DNA alterations that are present in MIBCs, and several
groups also employed whole genome mRNA expression profiling to identify intrinsic
basal and luminal subtypes of MIBCs that are similar to the corresponding subtypes
of breast cancer (4, 7, 8, 11). While several studies have focused on the impact of
DNA mutations, copy number variations and translocations, non-protein coding
RNAs have been overlooked on the large scale.
Non-protein coding RNAs, including miRNAs and lncRNAs, have been shown
to have a greater impact on evolutionary diversity than protein-coding mRNAs (109,
110). The effects of miRNAs on cancer biology have been studied, and their primary
function is widely understood to inhibit expression of proteins encoded by their
mRNA targets. However, lncRNAs are a little more of a mystery since they are not
as well understood, but have been observed to contribute to tumor initiation and
progression (111-113). While lncRNAs have been implicated in various biological
functions, the mechanisms by which they exert their activity is largely unknown.
Until recently, whole genome approaches to measure lncRNA expression patterns
were not available, which has limited the scope of investigations to date. In this
chapter, we developed bioinformatic methods to extract whole genome lncRNA
expression patterns from the TCGA’s RNA-seq data to examine whether we could
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also identify lncRNA-based intrinsic subtypes of MIBC. We seek to not only deepen
our current understanding of MIBC biology, but to also identify potential biomarkers
to clinically characterize the disease.

4.2. Results
4.2.1. Identification of lncRNA-based MIBC subtypes
We examined patterns of whole-genome lncRNA expression in TCGA’s MIBC
RNA-seq dataset (n=407) by re-aligning and re-annotating the data. A total of
31,191 lncRNAs were isolated and analyzed. After filtering based on level of
expression, 1,827 lncRNAs were found to be expressed by MIBCs. We used the
1,827 lncRNAs to perform unsupervised consensus clustering (CC) to determine the
number of intrinsic lncRNA-associated molecular subtypes that were present. The
results revealed the presence of 3 distinct clusters (Figure 14A). We compared the
lncRNA subtypes to the mRNA based basal, luminal, and p53-like subtypes as
identified by MDA’s oneNN model (11), and found 75% concordance. We noticed
that the third cluster identified by CC contained mixed expression of the basal and
luminal specific mRNAs (Figure 14B), similar to our previous findings (114),
suggesting a 2-cluster solution may be more robust.
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Figure 14: LncRNA consensus clustering identifies a 3-cluster solution.
LncRNA consensus clustering was performed with TCGA’s cohort (n=407) and a 3cluster solution was identified as mathematically optimal. A. Consensus clustering
results in 3 distinct clusters. B. Visualization of MDA basal markers (top), MDA
luminal markers (middle), and MDA p53-like tumors (bottom). Color bars: PAM
subtype – basal (red), luminal (green); Lund subtype – GU (red), Infil (green), SCCL
(blue), UroA (purple), UroB(yellow); oneNN subtype – basal (red), luminal (green),
p53-like (purple); lncRNA consensus clustering – basal (red), luminal (green), p53like (purple). Relative expression of luminal genes GATA3 and PPARG are also
visualized.
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We chose to focus on a 2-cluster solution, focusing on the intrinsic basal and
luminal subtypes, since these appeared to be more stable (Figure 15). When the
lncRNA-based basal and luminal subtypes were compared to the mRNA PAMidentified basal and luminal subtypes (114), there was 98% concordance,
suggesting that lncRNA expression alone could be used to identify the intrinsic basal
and luminal subtypes of MIBC. We also compared the lncRNA CC subtype
identifications to the oneNN basal and luminal classifications, in the absence of the
p53-like tumors (11), and we also see 98% concordance between the calls,
suggesting the basal and luminal intrinsic subtypes are reproducible.
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Figure 15: 2-cluster lncRNA consensus clustering solution. LncRNA consensus
clustering was performed with TCGA’s cohort, in the absence of “p53-like” tumors (n
= 308) and a 2-cluster solution was identified. A. LncRNA consensus clustering
results in 2 distinct clusters. B. Visualization of basal markers (top), cell cycle
markers (middle - top), extracellular matrix markers (middle - bottom), and luminal
markers (bottom). Color bars: PAM subtype – basal (red), luminal (green); Lund
subtype – GU (red), Infil (green), SCCL (blue), UroA (purple), UroB(yellow); oneNN
subtype – basal (red), luminal (green), p53-like (purple); lncRNA consensus
clustering – basal (red), luminal (green). Relative expression of luminal genes
GATA3 and PPARG are also visualized.
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4.2.2. mRNA expression in the lncRNA-defined subtypes
We used the mRNA expression patterns in the lncRNA-defined basal and
luminal MIBCs to perform gene set enrichment analysis (GSEA). The results
indicated that the basal and luminal MIBC clusters identified by lncRNAs were very
similar to basal and luminal breast cancers, as indicated by the significant
enrichment of the CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_UP gene
signature in the luminal subtype and
CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DOWN gene signature in
the basal subtype (115). Also, similar to previous reports in bladder and breast
cancers, the basal subtype identified by lncRNA expression had overall poor survival
when compared to the luminal subtype (4, 7, 11, 114) (Figure 16).
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Figure 16: Survival outcomes based on the lncRNA defined basal and luminal
clusters. Kaplan-Meier plot of the overall survival outcomes of the lncRNA defined
basal and luminal clusters in TCGA’s cohort (n = 308). The basal subtype exhibited
overall poor survival outcomes (p = 0.038).
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4.2.3. Differential lncRNA expression
Differential expression analysis of the lncRNAs between the basal and
luminal subtypes identified 430 lncRNAs to be significantly differentially expressed
(Figure 17). The basal subtype overexpressed 204 lncRNAs, while the luminal
subtype overexpressed 226 lncRNAs. A closer analysis of the differentially
expressed lncRNAs identified some lncRNAs with previously established functional
activity in cancer. The basal subtype overexpressed several lncRNAs that have
been previously studied, including MIAT, MEG3, and MIR155HG, while the luminal
subtype overexpressed UCA1. Interestingly, the basal subtype expressed
MIR155HG, which has been associated with an aggressive phenotype and
activation of epithelial-mesenchymal transition (EMT) (116). There was also high
expression of MEG3, which has been previously characterized as a tumor
suppressor in bladder cancer since it is typically expressed by normal tissues and
lost in bladder cancer (69, 117). Urothelial carcinoma associated 1 (UCA1) has
been identified as a biomarker for bladder cancer in urine sediment (65), and in this
study, we found it to be significantly upregulated in luminal MIBC when compared to
basal MIBCs.

75

Figure 17: Visualization of the 430 differentially expressed lncRNAs. The
heatmap depicts relative expression of the 430 significantly differentially expressed
lncRNAs in TCGA’s cohort (n = 308). Color bars: PAM subtype – basal (red),
luminal (green); Lund subtype – GU (red), Infil (green), SCCL (blue), UroA (purple),
UroB(yellow); oneNN subtype – basal (red), luminal (green), p53-like (purple);
lncRNA consensus clustering – basal (red), luminal (green). Relative expression of
luminal genes GATA3 and PPARG are also visualized.
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4.2.4. LncRNA-based PAM classifier
We next sought to develop a lncRNA-based PAM classifier, which could
accurately identify the basal and luminal subtypes of MIBC. Using TCGA’s cohort
and the lncRNA CC subtype identifications, PAM identified solutions ranging from 53
(Δ = 8.678, overall error rate = 0.013) to 9 lncRNAs (Δ = 12.475, overall error rate =
0.045) that would be optimal for assigning cluster membership (Figure 18). However,
due to a lack of publicly available MIBC RNA-sequencing cohorts, the lncRNA-based
PAM classifier could not be validated.
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Figure 18: LncRNA-based PAM classifier training. A. PAM training solution
with 53 lncRNAs (Δ = 8.678, overall error rate = 0.013). B. PAM training solution
with 28 lncRNAs (Δ = 9.763, overall error rate = 0.016). C. PAM training solution
with 17 lncRNAs (Δ = 10.848, overall error rate = 0.023). D. PAM training solution
with 9 lncRNAs (Δ = 12.475, overall error rate = 0.045). Color bar: lncRNACC basal (red), luminal (blue).
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4.2.5. Identification of sub-clusters within the basal and luminal subtypes
We further examined the presence of sub-clusters within the intrinsic basal
and luminal lncRNA subtypes. To study this, we performed unsupervised
consensus clustering on the 137 basal tumors identified by lncRNA CC. This
revealed the presence of 2 clusters (Figure 19A). We used canonical basal markers
(KRT5, KRT6A, KRT6B, KRT6C) and markers of EMT (ZEB1/2, TWIST1, FN1) to
classify the tumors as either “epithelial” or “mesenchymal” (Figure 20). Comparison
of the sub-clusters as identified by mRNA signature or lncRNA CC revealed 90%
concordance. There were 129 lncRNAs significantly differentially expressed
between the two basal sub-clusters, 62 over-expressed by cluster2 (“epithelial”), and
67 over-expressed in cluster1 (“mesenchymal”) (Figure 19B). When comparing the
two basal sub-clusters, there was a significant difference in survival outcomes
(p=0.027), with the “mesenchymal” tumors showing poor outcomes (Figure 19C).
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Figure 19: LncRNA consensus clustering identifies two subsets within the
basal subtype. The basal tumors identified by lncRNA consensus clustering were
subjected to a second round of unsupervised consensus clustering. A. Consensus
clustering identifies two subsets within the basal subtype. B. Visualization of the 129
significantly differentially expressed lncRNAs between the two subsets. C. KaplanMeier plot shows that cluster1 (“mesenchymal” sub-cluster) exhibits poor overall
survival outcomes (p = 0.027). Color bars: Lund subtype – GU (red), Infil (green),
SCCL (blue), UroA (purple), UroB(yellow); basal subtype – epithelial (yellow),
mesenchymal (purple), gray (data not available); lncRNA consensus clustering –
cluster1 (red), cluster2 (light blue). Relative expression of epithelial marker CDH1,
and mesenchymal marker ZEB1 are also visualized.
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Figure 20: Identification of basal sub-clusters by mRNA expression signature.
Basal tumors in TCGA’s cohort of 408 patient samples were isolated using a PAM
classifier based on mRNA expression. Supervised hierarchical clustering with
epithelial markers (top) and mesenchymal markers (bottom) identified two subclusters of basal tumors. Color bars: PAM subtype – basal (red); Lund subtype –
GU (red), Infil (green), SCCL (blue), UroA (purple), UroB(yellow); oneNN subtype –
basal (red), luminal (green), p53-like (purple); sub-cluster – epithelial (red),
mesenchymal (yellow).
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GSEA comparing the mRNA expression patterns between the two subclusters confirmed a down-regulation of metastasis markers in the “epithelial” subcluster (Figure 21). We found the
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP gene set
(Figure 21A) (115), and the JAEGER_METASTASIS_DN gene set (Figure 21B)
(118) to be significantly enriched in the “epithelial” basal subset. We followed up this
observation by generating an EMT lncRNA expression signature that was derived
from cell line expression profiles that are currently available through the Cancer Cell
Line Encyclopedia (CCLE). Visualization of this signature showed relatively high
expression of EMT lncRNAs in the mesenchymal sub-cluster (Figure 22A), and
GSEA analyses showed significant enrichment of the down-regulated lncRNAs in
mesenchymal cell lines in the “epithelial” sub-cluster (p = 0, FDR = 0) (Figure 22B).
Interestingly, the “mesenchymal” sub-cluster had over-expression of two lncRNAs
that are considered to be tumor suppressors, MIAT and MEG3 (60, 69, 117, 119),
while the lncRNAs over-expressed in the “epithelial” sub-cluster have not been
studied previously. Again, we observed high expression of MEG3 was associated
with poor overall survival.
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Figure 21: The two subsets of the basal subtype are characterized by
differences in expression of mesenchymal gene sets. A. GSEA analyses
identified significant enrichment of the
CHARAFE_BREAST_CANCER_BASAL_VS_MESENCHYMAL_UP gene set in the
“epithelial” subset (p = 0, FDR = 0.00168). B. GSEA analyses identified significant
enrichment of the JAEGER_METASTASIS_DN gene set in the “epithelial” subset (p
= 0, FDR = 0.00126).
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Figure 22: EMT lncRNA expression signature in the basal subtype. A.
Visualization of the EMT lncRNA expression signature in the basal subtype identified
by lncRNA expression. B. GSEA analyses with a signature of significantly downregulated lncRNAs in mesenchymal cell lines, showed significant enrichment in the
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“epithelial” sub-cluster (p = 0, FDR = 0). Color bars: Lund subtype – GU (red), Infil
(green), SCCL (blue), UroA (purple), UroB(yellow); basal subtype – epithelial
(yellow), mesenchymal (purple), gray (data not available); lncRNA consensus
clustering – cluster1 (red), cluster2 (light blue). Relative expression of epithelial
marker CDH1, and mesenchymal marker ZEB1 are also visualized.
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We performed the same unsupervised consensus clustering on the 171
luminal tumors identified by lncRNA CC. This revealed the presence of 2 clusters
(Figure 23). We opted to compare these two sub-clusters to the luminal subtypes
previously identified by the Lund group, genomically unstable (GU) and urobasal A
(UroA) (8). Surprisingly, we found that one of the luminal sub-clusters contained
only UroA tumors (cluster2), while the other sub-cluster contained a majority GU
tumors along with some UroA tumors (cluster1). We studied the differentially
expressed lncRNAs between the two luminal sub-clusters, resulting in 191
significant differentially expressed lncRNAs. There were 58 up-regulated in the
“UroA” sub-cluster, and 133 up-regulated in the “GU” sub-cluster (Figure 23B). The
“UroA” sub-cluster was enriched for MIR31HG and UCA1, while the “GU” sub-cluster
was enriched for DNM3OS, SNHG18, and CDKN2B-AS1. When looking at the two
sub-clusters of luminal, there was no difference in survival outcomes (Figure 23C).
GSEA comparing the two sub-clusters of the luminal subtype identified a
significant difference in grade based on the presence of the
LINDGREN_BLADDER_CANCER_CLUSTER_3_DN gene set in the “UroA” tumors,
and the LINDGREN_BLADDER_CANCER_CLUSTER_3_UP gene set in the “GU”
tumors (120). This suggested that the “UroA” sub-cluster was enriched with downregulated genes in high grade tumors (Figure 24A), and the “GU” sub-cluster was
enriched with up-regulated genes in high grade tumors (Figure 24B).
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Figure 23: LncRNA consensus clustering identifies two subsets within the
luminal subtype. The luminal tumors identified by lncRNA consensus clustering
were subjected to a second round of unsupervised consensus clustering. A.
Consensus clustering identifies two subsets within the luminal subtype. B.
Visualization of the 191 significantly differentially expressed lncRNAs between the
two subsets. C. Kaplan-Meier plot shows no significant survival differences between
the two subsets (p = 0.35). Color bars: Lund subtype – GU (red), Infil (green), SCCL
(blue), UroA (purple), UroB(yellow); basal subtype – epithelial (yellow),
mesenchymal (purple), gray (data not available); lncRNA consensus clustering –
cluster1 (red), cluster2 (light blue). Relative expression of luminal markers GATA3
and PPARG are also visualized.
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Figure 24: The two subsets of the luminal subtype are characterized by
differences in expression of high-grade bladder cancer gene sets. A. The
LINDGREN_BLADDER_CANCER_CLUSTER_3_DN gene set is significantly
enriched in the “UroA” tumors, suggesting that the “UroA” subset is enriched with
tumors of a lower grade (p = 0, FDR = 0). B. The
LINDGREN_BLADDER_CANCER_CLUSTER_3_UP gene set is enriched in the
“GU” tumors (p = 0, FDR = 0.24), suggesting that the “GU” subset is enriched with
high grade tumors.
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4.2.6. Summary of differentially expressed lncRNAs
We summarized the findings and identified 40 lncRNAs that were specific to
the basal and luminal intrinsic subtypes, as well as to the sub-clusters identified
within each intrinsic subtype (Figure 25). The top 10 lncRNAs identified to be
overexpressed in the “UroA” sub-cluster were relatively expressed in the other
luminal sub-cluster, but were down-regulated in the two basal clusters. The lncRNAs
specific to the “GU” sub-cluster exhibited a similar pattern of expression, with slight
expression in the other luminal sub-cluster and down-regulation in the two basal
clusters. The lncRNAs overexpressed by the basal “epithelial” sub-cluster were
significantly down-regulated in the basal “mesenchymal” sub-cluster, and exhibited
relatively low expression across the other subsets. While the lncRNAs specific to
the basal “mesenchymal” sub-cluster were expressed by the basal “epithelial” subcluster to a slightly lower degree, and were relatively down-regulated in the luminal
clusters.
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Figure 25: 40-lncRNA signature distinguishes the four lncRNA clusters. The
heatmap depicts relative expression of the 40 lncRNAs that distinguish the four
lncRNA identified clusters. Color bar: luminal – “UroA” (blue), luminal – “GU” (light
blue), basal – “epithelial” (red), basal – “mesenchymal” (yellow).
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4.3. Discussion
Emerging evidence implicates long non-coding RNAs (lncRNAs) in the
regulation of crucial biological processes in cancer. Using unsupervised
hierarchical analyses of whole genome lncRNA expression to identify intrinsic
lncRNA subtypes of human muscle-invasive bladder cancers (MIBCs), we identified
two lncRNA MIBC subtypes that were almost identical to the recently discovered
intrinsic basal and luminal subtypes identified through mRNA expression profiling.
The basal lncRNA subtype could be further subdivided into “epithelial’ and
“mesenchymal” subtypes and the luminal lncRNA subtype could be further
subdivided into “UroA” and “GU” subtypes. We see a difference in survival
outcomes between the sub-clusters of basal, but there is no survival difference
between the sub-clusters of the luminal subtype. However, GSEA did reveal a
potential difference in tumor grade between the two luminal sub-clusters.
Analysis of the significant differentially expressed lncRNAs will add a
significant layer of complexity to our current understanding of MIBC development
and progression. The lncRNAs over-expressed in the basal subtype were
commonly associated with squamous cancers or regulators of EMT. Two of the
basal lncRNAs, RP11-132A1.4 and RP11-357H14.19, were shown to be upregulated in hypopharyngeal squamous cell carcinomas and head and neck
squamous cell carcinomas, respectively (121, 122). RP11-357H14.19 also plays
host to miR-196a, which is also over-expressed in basal MIBCs (122). ZEB1-AS1 is
overexpressed in esophageal squamous cell carcinomas, and is also associated
with lymph node metastasis and poor overall survival and disease specific survival
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(123). Other over-expressed basal lncRNAs include DNM3OS, which is predicted to
be under the control of TWIST1, a key regulator of EMT (124). RP11-38P2.2 was
also overexpressed in basal MIBCs and is predicted to be controlled by miR-205-5p,
a common inhibitor of EMT by targeting ZEB1 (125). However, it is also suggested
that this lncRNA acts as a sponge RNA to interact with and suppress miR-205
expression to maintain totipotency of cells (125). The most interesting
overexpressed lncRNA in the basal cancers was MEG3, which has been identified to
possess tumor suppressive activity as it is lowly expressed in tumor tissues when
compared to normal tissues (70, 126-128). In this present study, we see that high
expression of MEG3 is associated with a lethal sub-cluster of basal tumors,
suggesting that more studies need to be done to determine the role of MEG3 in the
progression of MIBC.
Several lncRNAs overexpressed in the luminal subtype were associated with
response to cisplatin or with better survival outcomes. RP11-789C1.1 expression
was associated with better survival outcomes in gastric cancers, lower rates of
metastasis and lower tumor stage (129). RP11-363E7.4 was upregulated after
cisplatin exposure, and was associated with up-regulated p53 pathway genes (130).
It has been shown that cisplatin treatment upregulates the expression of UCA1, and
is further increased in cisplatin-resistant bladder cancer cells (131). Studies have
shown that over-expression increases cell viability during cisplatin treatment,
whereas UCA1 knockdown partially overcomes drug resistance (131). Since the
detection of UCA1 in urine sediment has proven to be highly sensitive and specific
for diagnosing bladder carcinoma, it may also be developed into a biomarker to
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predict sensitivity to chemotherapy in MIBC (65). UCA1 is also suggested to be
regulated by CEBPA by ChIP analyses, a transcription factor found commonly upregulated in luminal MIBCs (132). However, UCA1 has 3 different splice variants,
one of which has been suggested to induce EMT and increase the migratory and
invasive abilities of bladder cancer cells by repressing miR-145 expression (133).
Overall, we saw high concordance between the basal and luminal
classifications made by using lncRNA and mRNA expression demonstrating that the
intrinsic basal and luminal subtypes of MIBC are robust, and that lncRNA expression
may serve as a surrogate for identifying mRNA based subtypes. This study also
introduces the potential of using relative lncRNA expression to identify tumor
subtype. Since the detection of one bladder cancer associated lncRNA in urine
sediment has already been established, it should be reasonable to develop a urine
based test to quantify lncRNA expression and subsequently identify tumor subtype
non-invasively in the near future.
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Chapter 5:
Summary & Future Directions
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5. Conclusions
Taken together, this dissertation outlines new findings that add significant
complexity to the currently understood biology underlying the heterogeneity of MIBC,
but also reinforces the presence of intrinsic subtypes of MIBC. This chapter will
review the conclusions made from Chapters 3 and 4, and discuss possible future
work to expand on the conclusions made.

5.1. Summary
Chapter 3: miRNA expression profiles identify subtypes of MIBC. The
work presented in Chapter 3 revolved around two major goals. The first goal was to
show that the previously identified intrinsic subtypes of MIBC were reproducible (4,
7, 8, 11). Previous findings were confirmed by subjecting unsupervised analyses to
the largest, high-quality data set that is currently available for MIBC from TCGA
(n=405). We identified three clusters that were reminiscent of the clusters previously
identified (11), including stable basal and luminal subtypes and an “infiltrated”
unstable cluster. We then developed an mRNA-PAM classifier that consisted of 593
mRNAs, that was validated in 62 FF samples from our own MDA cohort
(GSE48075).
The second goal of this chapter was to identify miRNAs that could optimally
distinguish the basal and luminal subtypes of MIBC, which could lead to the
development of better diagnostic tools for MIBC. Since there is only one MIBC
cohort with matched mRNA and miRNA expression, TCGA’s cohort, there was a
need to develop a validation cohort. We performed miRNA-sequencing on a cohort
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of 62 FF MIBCs, that we have matched whole genome expression profiling data for.
An unsupervised approach using miRNA expression alone did not yield positive
results, so using a supervised approach we were able to develop a 63-miRNA PAM
classifier that identified basal and luminal tumors with more than 80% accuracy. We
noticed that the miRNA expression patterns of the basal and luminal subtypes
reiterated known biological properties of the subtypes.

Chapter 4: LncRNA expression profiles identify subtypes of MIBC. Since
recent work has implicated lncRNAs in the regulation of the hallmarks of cancer, we
sought to understand the lncRNA expression patterns that were associated with the
basal and luminal subtypes of MIBC. We extracted lncRNA expression data from
TCGA’s RNA-seq data set (n=407), and performed unsupervised analyses. Based
solely on lncRNA expression we identified the basal and luminal subtypes with over
95% accuracy. The lncRNAs overexpressed by basal tumors were associated with
transcription factors involved in EMT and associated with squamous cancers, which
are both characteristics of basal MIBCs. The overexpressed lncRNAs in luminal
tumors were primarily associated with good outcomes, or the development of
cisplatin resistance.
We also identified subsets within the basal and luminal subtypes. Within the
basal subtype, we identified a larger subset that exhibited “epithelial” properties and
a smaller subset that exhibited “mesenchymal” properties, which had poor survival
outcomes. The luminal subtype could be further subdivided into a “UroA” subtype,
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and a “GU” subtype that is enriched with mRNA expression patterns of high grade
bladder cancers.

5.2. Future Directions
In order to expand upon the work presented here, there are several follow up
experiments that could be performed. First and foremost, the development of a
clinical diagnostic tool is greatly needed and should be prioritized. Since ncRNAs
are considered to be relatively stable in bodily fluids, and lncRNAs have been
previously measured in urine sediment, it should be feasible to develop a clinically
relevant tool. However, there are several obstacles that need to be addressed
before development would be possible. The first obstacle would be optimizing the
RNA isolation protocol. We would need to be able to acquire at least 100 ng of total
RNA to perform a custom Nanostring assay with both miRNAs and lncRNAs, or
more if miRNA-sequencing and RNA-sequencing is desired. Once the isolation
protocol is in place, we would need to decide on either a custom panel of miRNAs
and lncRNAs that could identify the intrinsic subtypes or if we want to perform
sequencing. Lastly, we would need to perform an independent experiment to
confirm that the expression profiles observed in the body fluids are comparable to
the expression patterns observed in the primary tumor. The test would then need to
be validated and approved for clinical use.
Another important question that needs to be addressed is, which ncRNAs are
the most important for basal and luminal gene expression in bladder cancer. This
question could be addressed by performing knockdowns of the most deregulated
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ncRNAs in basal or luminal cell lines, followed by whole genome expression
analysis. If a phenotypic or transcriptomic subtype change were observed after
knockdown, then that ncRNA may play an important role in regulating subtype
expression profiles. We may also opt to perform similar analyses in breast cancer,
to determine which ncRNAs are specific to the basal and luminal subtypes of
bladder cancer or to develop a test that could identify basal and luminal subtypes
regardless of tumor site. Once these ncRNAs are identified, the molecular
mechanism by which they control gene expression would need to be explored. This
would be a tremendous undertaking, but it would help the research community
understand the underlying biology of basal and luminal expression subtypes. An
important distinction that would need to be made is, are the ncRNAs controlling the
transcription factors that are implicated as upstream regulators of the subtype, or are
the ncRNAs regulating downstream expression of the upstream regulators. This
could lead to the subsequent identification of druggable targets, providing MIBC
patients with additional treatment options.
Lastly, in order to complete the work presented in chapter 4, it will be
important to develop a validation cohort to confirm our findings. This could be
addressed by performing RNA-sequencing on our cohort of 62 FF tissues, and
subsequently using bioinformatic methods to isolate the lncRNA expression profiles.
Ultimately, validating the lncRNA findings in an independent cohort will add a
significant amount of relevance to this work.
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5.3. Final Discussion
When we look at the data presented as a whole, we see that the expression
patterns of ncRNAs can provide insight into the basal and luminal MIBCs since we
see similar characteristics of the subtypes regardless of RNA type used to identify
subtype. The results also indicate the presence of sub-clusters within the basal and
luminal subtypes, which are distinguished by infiltration or the presence of
mesenchymal markers. However, a major question that remains is, how exactly do
the identified miRNAs and lncRNAs affect the gene expression patterns observed
that distinguish the basal and luminal subtypes of MIBC.
One way to begin to address this question is to look at correlations between
lncRNA and miRNA expression, as well as the mRNA targets of the miRNA. Using
TCGA’s cohort, we correlated the overexpressed lncRNAs in luminal tumors with
miRNA expression. We observed that several luminal lncRNAs were positively
correlated with miR-934, miR-429, miR-200a and miR-200c, and was negatively
correlated with miR-146b. When we looked at the lncRNAs overexpressed in basal
tumors, we see significant negative correlations with the miR-200 family members
(miR-200a, miR-200b, miR-429, miR-141, miR-200c), and positive correlations with
miR-142, miR-155, and miR-146b. Based on our previous studies, we see that miR934, and miR-200 family members are overexpressed in luminal tumors, while miR146b, miR-142 and miR-155 are overexpressed in basal tumors (114). While the
function of miR-934 has not been elucidated, the other miRNAs identified have been
implicated in EMT. The miR-200 family directly target transcriptional activators of
EMT, including ZEB1/2 (34), miR-155 is positively correlated with metastasis in
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breast cancer (88, 134, 135), miR-146b has been implicated in promoting metastasis
in some tissues and inhibiting metastasis in others (136, 137), and miR-142 has
been implicated as a metastasis suppressor (138, 139).
These results suggest that miRNAs and lncRNAs play a concerted effort to
regulate gene expression. MiRNAs have been shown to regulate lncRNAs by
binding to regions similar to their mRNA targets causing lncRNA instability, and
lncRNAs have been shown to regulate miRNA expression through multiple
mechanisms. LncRNAs can regulate miRNA function by acting as a sponge, can
directly bind to miRNA to communicate with downstream RNA targets (140), and can
compete with miRNA binding to alleviate mRNA suppression (141). LncRNAs can
also act as hosts to miRNAs, with approximately 10% of lncRNA genes playing host
to miRNAs (142) either in an intron or exon. For example, the H19 lncRNA is a
precursor for miR-675 that functions as a tumor suppressor by inhibiting cellular
proliferation (143). The interplay between miRNA expression and lncRNA
expression implicates ncRNAs as vital modulators of gene expression, however the
mechanisms by which they do so remain to be elucidated in MIBC.
Most importantly, this work implicates both lncRNAs and miRNAs as potential
diagnostic biomarkers in MIBC. In particular, lncRNA expression analyses were
highly consistent with mRNA expression analyses, suggesting an alternative method
to diagnosing and characterizing MIBCs. Also, due to their high specificity, lncRNA
expression may be a better indicator of disease state.

101

BIBLIOGRAPHY
1.

Society, A. C. 2017. Cancer Facts & FIgures 2017. Atlanta, Ga.

2.

Botteman, M. F., C. L. Pashos, A. Redaelli, B. Laskin, and R. Hauser. 2003.
The health economics of bladder cancer: a comprehensive review of the
published literature. Pharmacoeconomics 21: 1315-1330.

3.

Shah, J. B., D. J. McConkey, and C. P. Dinney. 2011. New strategies in
muscle-invasive bladder cancer: on the road to personalized medicine. Clin
Cancer Res 17: 2608-2612.

4.

Cancer Genome Atlas Research, N. 2014. Comprehensive molecular
characterization of urothelial bladder carcinoma. Nature 507: 315-322.

5.

Powles, T., J. P. Eder, G. D. Fine, F. S. Braiteh, Y. Loriot, C. Cruz, J.
Bellmunt, H. A. Burris, D. P. Petrylak, S. L. Teng, X. Shen, Z. Boyd, P. S.
Hegde, D. S. Chen, and N. J. Vogelzang. 2014. MPDL3280A (anti-PD-L1)
treatment leads to clinical activity in metastatic bladder cancer. Nature 515:
558-562.

6.

Rosenberg, J. E., J. Hoffman-Censits, T. Powles, M. S. van der Heijden, A. V.
Balar, A. Necchi, N. Dawson, P. H. O'Donnell, A. Balmanoukian, Y. Loriot, S.
Srinivas, M. M. Retz, P. Grivas, R. W. Joseph, M. D. Galsky, M. T. Fleming,
D. P. Petrylak, J. L. Perez-Gracia, H. A. Burris, D. Castellano, C. Canil, J.
Bellmunt, D. Bajorin, D. Nickles, R. Bourgon, G. M. Frampton, N. Cui, S.
Mariathasan, O. Abidoye, G. D. Fine, and R. Dreicer. 2016. Atezolizumab in
patients with locally advanced and metastatic urothelial carcinoma who have

102

progressed following treatment with platinum-based chemotherapy: a singlearm, multicentre, phase 2 trial. Lancet 387: 1909-1920.
7.

Damrauer, J. S., K. A. Hoadley, D. D. Chism, C. Fan, C. J. Tiganelli, S. E.
Wobker, J. J. Yeh, M. I. Milowsky, G. Iyer, J. S. Parker, and W. Y. Kim. 2014.
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast
cancer biology. Proc Natl Acad Sci U S A 111: 3110-3115.

8.

Sjodahl, G., M. Lauss, K. Lovgren, G. Chebil, S. Gudjonsson, S. Veerla, O.
Patschan, M. Aine, M. Ferno, M. Ringner, W. Mansson, F. Liedberg, D.
Lindgren, and M. Hoglund. 2012. A molecular taxonomy for urothelial
carcinoma. Clin Cancer Res 18: 3377-3386.

9.

Perou, C. M., T. Sorlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees,
J. R. Pollack, D. T. Ross, H. Johnsen, L. A. Akslen, O. Fluge, A.
Pergamenschikov, C. Williams, S. X. Zhu, P. E. Lonning, A. L. Borresen-Dale,
P. O. Brown, and D. Botstein. 2000. Molecular portraits of human breast
tumours. Nature 406: 747-752.

10.

Sorlie, T., C. M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T.
Hastie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, T. Thorsen, H. Quist, J. C.
Matese, P. O. Brown, D. Botstein, P. E. Lonning, and A. L. Borresen-Dale.
2001. Gene expression patterns of breast carcinomas distinguish tumor
subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 1086910874.

11.

Choi, W., S. Porten, S. Kim, D. Willis, E. R. Plimack, J. Hoffman-Censits, B.
Roth, T. Cheng, M. Tran, I. L. Lee, J. Melquist, J. Bondaruk, T. Majewski, S.

103

Zhang, S. Pretzsch, K. Baggerly, A. Siefker-Radtke, B. Czerniak, C. P.
Dinney, and D. J. McConkey. 2014. Identification of distinct basal and luminal
subtypes of muscle-invasive bladder cancer with different sensitivities to
frontline chemotherapy. Cancer Cell 25: 152-165.
12.

Amorim, M., S. Salta, R. Henrique, and C. Jeronimo. 2016. Decoding the
usefulness of non-coding RNAs as breast cancer markers. J Transl Med 14:
265.

13.

Liep, J., A. Rabien, and K. Jung. 2012. Feedback networks between
microRNAs and epigenetic modifications in urological tumors. Epigenetics 7:
315-325.

14.

Lee, R. C., R. L. Feinbaum, and V. Ambros. 1993. The C. elegans
heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell 75: 843-854.

15.

Reinhart, B. J., F. J. Slack, M. Basson, A. E. Pasquinelli, J. C. Bettinger, A. E.
Rougvie, H. R. Horvitz, and G. Ruvkun. 2000. The 21-nucleotide let-7 RNA
regulates developmental timing in Caenorhabditis elegans. Nature 403: 901906.

16.

Pasquinelli, A. E., B. J. Reinhart, F. Slack, M. Q. Martindale, M. I. Kuroda, B.
Maller, D. C. Hayward, E. E. Ball, B. Degnan, P. Muller, J. Spring, A.
Srinivasan, M. Fishman, J. Finnerty, J. Corbo, M. Levine, P. Leahy, E.
Davidson, and G. Ruvkun. 2000. Conservation of the sequence and temporal
expression of let-7 heterochronic regulatory RNA. Nature 408: 86-89.

104

17.

Kaufman, E. J., and E. A. Miska. 2010. The microRNAs of Caenorhabditis
elegans. Semin Cell Dev Biol 21: 728-737.

18.

Guo, H., N. T. Ingolia, J. S. Weissman, and D. P. Bartel. 2010. Mammalian
microRNAs predominantly act to decrease target mRNA levels. Nature 466:
835-840.

19.

Eiring, A. M., J. G. Harb, P. Neviani, C. Garton, J. J. Oaks, R. Spizzo, S. Liu,
S. Schwind, R. Santhanam, C. J. Hickey, H. Becker, J. C. Chandler, R.
Andino, J. Cortes, P. Hokland, C. S. Huettner, R. Bhatia, D. C. Roy, S. A.
Liebhaber, M. A. Caligiuri, G. Marcucci, R. Garzon, C. M. Croce, G. A. Calin,
and D. Perrotti. 2010. miR-328 functions as an RNA decoy to modulate
hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 140: 652665.

20.

Calin, G. A., C. D. Dumitru, M. Shimizu, R. Bichi, S. Zupo, E. Noch, H. Aldler,
S. Rattan, M. Keating, K. Rai, L. Rassenti, T. Kipps, M. Negrini, F. Bullrich,
and C. M. Croce. 2002. Frequent deletions and down-regulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.
Proc Natl Acad Sci U S A 99: 15524-15529.

21.

Almeida, M. I., R. M. Reis, and G. A. Calin. 2011. MicroRNA history:
discovery, recent applications, and next frontiers. Mutat Res 717: 1-8.

22.

Calin, G. A., C. G. Liu, C. Sevignani, M. Ferracin, N. Felli, C. D. Dumitru, M.
Shimizu, A. Cimmino, S. Zupo, M. Dono, M. L. Dell'Aquila, H. Alder, L.
Rassenti, T. J. Kipps, F. Bullrich, M. Negrini, and C. M. Croce. 2004.

105

MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic
leukemias. Proc Natl Acad Sci U S A 101: 11755-11760.
23.

Croce, C. M. 2009. Causes and consequences of microRNA dysregulation in
cancer. Nat Rev Genet 10: 704-714.

24.

He, L., J. M. Thomson, M. T. Hemann, E. Hernando-Monge, D. Mu, S.
Goodson, S. Powers, C. Cordon-Cardo, S. W. Lowe, G. J. Hannon, and S. M.
Hammond. 2005. A microRNA polycistron as a potential human oncogene.
Nature 435: 828-833.

25.

Medina, P. P., M. Nolde, and F. J. Slack. 2010. OncomiR addiction in an in
vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 467: 86-90.

26.

Garzon, R., G. A. Calin, and C. M. Croce. 2009. MicroRNAs in Cancer. Annu
Rev Med 60: 167-179.

27.

O'Donnell, K. A., E. A. Wentzel, K. I. Zeller, C. V. Dang, and J. T. Mendell.
2005. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435:
839-843.

28.

He, L., X. He, S. W. Lowe, and G. J. Hannon. 2007. microRNAs join the p53
network--another piece in the tumour-suppression puzzle. Nat Rev Cancer 7:
819-822.

29.

Chuang, J. C., and P. A. Jones. 2007. Epigenetics and microRNAs. Pediatr
Res 61: 24R-29R.

30.

Saito, Y., G. Liang, G. Egger, J. M. Friedman, J. C. Chuang, G. A. Coetzee,
and P. A. Jones. 2006. Specific activation of microRNA-127 with

106

downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in
human cancer cells. Cancer Cell 9: 435-443.
31.

Nicoloso, M. S., R. Spizzo, M. Shimizu, S. Rossi, and G. A. Calin. 2009.
MicroRNAs--the micro steering wheel of tumour metastases. Nat Rev Cancer
9: 293-302.

32.

Ma, L., J. Teruya-Feldstein, and R. A. Weinberg. 2007. Tumour invasion and
metastasis initiated by microRNA-10b in breast cancer. Nature 449: 682-688.

33.

Tavazoie, S. F., C. Alarcon, T. Oskarsson, D. Padua, Q. Wang, P. D. Bos, W.
L. Gerald, and J. Massague. 2008. Endogenous human microRNAs that
suppress breast cancer metastasis. Nature 451: 147-152.

34.

Gregory, P. A., A. G. Bert, E. L. Paterson, S. C. Barry, A. Tsykin, G. Farshid,
M. A. Vadas, Y. Khew-Goodall, and G. J. Goodall. 2008. The miR-200 family
and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1
and SIP1. Nat Cell Biol 10: 593-601.

35.

Gottardo, F., C. G. Liu, M. Ferracin, G. A. Calin, M. Fassan, P. Bassi, C.
Sevignani, D. Byrne, M. Negrini, F. Pagano, L. G. Gomella, C. M. Croce, and
R. Baffa. 2007. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol
25: 387-392.

36.

Catto, J. W., M. F. Abbod, P. J. Wild, D. A. Linkens, C. Pilarsky, I. Rehman,
D. J. Rosario, S. Denzinger, M. Burger, R. Stoehr, R. Knuechel, A. Hartmann,
and F. C. Hamdy. 2010. The application of artificial intelligence to microarray
data: identification of a novel gene signature to identify bladder cancer
progression. Eur Urol 57: 398-406.

107

37.

Yates, D. R., I. Rehman, M. F. Abbod, M. Meuth, S. S. Cross, D. A. Linkens,
F. C. Hamdy, and J. W. Catto. 2007. Promoter hypermethylation identifies
progression risk in bladder cancer. Clin Cancer Res 13: 2046-2053.

38.

Catto, J. W., S. Miah, H. C. Owen, H. Bryant, K. Myers, E. Dudziec, S. Larre,
M. Milo, I. Rehman, D. J. Rosario, E. Di Martino, M. A. Knowles, M. Meuth, A.
L. Harris, and F. C. Hamdy. 2009. Distinct microRNA alterations characterize
high- and low-grade bladder cancer. Cancer Res 69: 8472-8481.

39.

Dyrskjot, L., M. S. Ostenfeld, J. B. Bramsen, A. N. Silahtaroglu, P. Lamy, R.
Ramanathan, N. Fristrup, J. L. Jensen, C. L. Andersen, K. Zieger, S.
Kauppinen, B. P. Ulhoi, J. Kjems, M. Borre, and T. F. Orntoft. 2009. Genomic
profiling of microRNAs in bladder cancer: miR-129 is associated with poor
outcome and promotes cell death in vitro. Cancer Res 69: 4851-4860.

40.

Guancial, E. A., J. Bellmunt, S. Yeh, J. E. Rosenberg, and D. M. Berman.
2014. The evolving understanding of microRNA in bladder cancer. Urol Oncol
32: 41 e31-40.

41.

Lowery, A. J., N. Miller, A. Devaney, R. E. McNeill, P. A. Davoren, C.
Lemetre, V. Benes, S. Schmidt, J. Blake, G. Ball, and M. J. Kerin. 2009.
MicroRNA signatures predict oestrogen receptor, progesterone receptor and
HER2/neu receptor status in breast cancer. Breast Cancer Res 11: R27.

42.

Lawrie, C. H., S. Gal, H. M. Dunlop, B. Pushkaran, A. P. Liggins, K. Pulford,
A. H. Banham, F. Pezzella, J. Boultwood, J. S. Wainscoat, C. S. Hatton, and
A. L. Harris. 2008. Detection of elevated levels of tumour-associated

108

microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J
Haematol 141: 672-675.
43.

Elkin, M., A. Shevelev, E. Schulze, M. Tykocinsky, M. Cooper, I. Ariel, D.
Pode, E. Kopf, N. de Groot, and A. Hochberg. 1995. The expression of the
imprinted H19 and IGF-2 genes in human bladder carcinoma. FEBS Lett 374:
57-61.

44.

Brannan, C. I., E. C. Dees, R. S. Ingram, and S. M. Tilghman. 1990. The
product of the H19 gene may function as an RNA. Mol Cell Biol 10: 28-36.

45.

Brown, C. J., A. Ballabio, J. L. Rupert, R. G. Lafreniere, M. Grompe, R.
Tonlorenzi, and H. F. Willard. 1991. A gene from the region of the human X
inactivation centre is expressed exclusively from the inactive X chromosome.
Nature 349: 38-44.

46.

Smith, C. M., and J. A. Steitz. 1998. Classification of gas5 as a multi-smallnucleolar-RNA (snoRNA) host gene and a member of the 5'-terminal
oligopyrimidine gene family reveals common features of snoRNA host genes.
Mol Cell Biol 18: 6897-6909.

47.

Wang, K. C., and H. Y. Chang. 2011. Molecular mechanisms of long
noncoding RNAs. Mol Cell 43: 904-914.

48.

Lee, C., and N. Kikyo. 2012. Strategies to identify long noncoding RNAs
involved in gene regulation. Cell Biosci 2: 37.

49.

Derrien, T., R. Johnson, G. Bussotti, A. Tanzer, S. Djebali, H. Tilgner, G.
Guernec, D. Martin, A. Merkel, D. G. Knowles, J. Lagarde, L. Veeravalli, X.
Ruan, Y. Ruan, T. Lassmann, P. Carninci, J. B. Brown, L. Lipovich, J. M.

109

Gonzalez, M. Thomas, C. A. Davis, R. Shiekhattar, T. R. Gingeras, T. J.
Hubbard, C. Notredame, J. Harrow, and R. Guigo. 2012. The GENCODE v7
catalog of human long noncoding RNAs: analysis of their gene structure,
evolution, and expression. Genome Res 22: 1775-1789.
50.

Djebali, S., C. A. Davis, A. Merkel, A. Dobin, T. Lassmann, A. Mortazavi, A.
Tanzer, J. Lagarde, W. Lin, F. Schlesinger, C. Xue, G. K. Marinov, J. Khatun,
B. A. Williams, C. Zaleski, J. Rozowsky, M. Roder, F. Kokocinski, R. F.
Abdelhamid, T. Alioto, I. Antoshechkin, M. T. Baer, N. S. Bar, P. Batut, K.
Bell, I. Bell, S. Chakrabortty, X. Chen, J. Chrast, J. Curado, T. Derrien, J.
Drenkow, E. Dumais, J. Dumais, R. Duttagupta, E. Falconnet, M. Fastuca, K.
Fejes-Toth, P. Ferreira, S. Foissac, M. J. Fullwood, H. Gao, D. Gonzalez, A.
Gordon, H. Gunawardena, C. Howald, S. Jha, R. Johnson, P. Kapranov, B.
King, C. Kingswood, O. J. Luo, E. Park, K. Persaud, J. B. Preall, P. Ribeca, B.
Risk, D. Robyr, M. Sammeth, L. Schaffer, L. H. See, A. Shahab, J. Skancke,
A. M. Suzuki, H. Takahashi, H. Tilgner, D. Trout, N. Walters, H. Wang, J.
Wrobel, Y. Yu, X. Ruan, Y. Hayashizaki, J. Harrow, M. Gerstein, T. Hubbard,
A. Reymond, S. E. Antonarakis, G. Hannon, M. C. Giddings, Y. Ruan, B.
Wold, P. Carninci, R. Guigo, and T. R. Gingeras. 2012. Landscape of
transcription in human cells. Nature 489: 101-108.

51.

Matouk, I. J., N. DeGroot, S. Mezan, S. Ayesh, R. Abu-lail, A. Hochberg, and
E. Galun. 2007. The H19 non-coding RNA is essential for human tumor
growth. PLoS One 2: e845.

110

52.

Takai, D., F. A. Gonzales, Y. C. Tsai, M. J. Thayer, and P. A. Jones. 2001.
Large scale mapping of methylcytosines in CTCF-binding sites in the human
H19 promoter and aberrant hypomethylation in human bladder cancer. Hum
Mol Genet 10: 2619-2626.

53.

Luo, M., Z. Li, W. Wang, Y. Zeng, Z. Liu, and J. Qiu. 2013. Long non-coding
RNA H19 increases bladder cancer metastasis by associating with EZH2 and
inhibiting E-cadherin expression. Cancer Lett 333: 213-221.

54.

Ayesh, S., I. Matouk, T. Schneider, P. Ohana, M. Laster, W. Al-Sharef, N. DeGroot, and A. Hochberg. 2002. Possible physiological role of H19 RNA. Mol
Carcinog 35: 63-74.

55.

Luo, M., Z. Li, W. Wang, Y. Zeng, Z. Liu, and J. Qiu. 2013. Upregulated H19
contributes to bladder cancer cell proliferation by regulating ID2 expression.
FEBS J 280: 1709-1716.

56.

Qiao, H. P., W. S. Gao, J. X. Huo, and Z. S. Yang. 2013. Long non-coding
RNA GAS5 functions as a tumor suppressor in renal cell carcinoma. Asian
Pac J Cancer Prev 14: 1077-1082.

57.

Kino, T., D. E. Hurt, T. Ichijo, N. Nader, and G. P. Chrousos. 2010. Noncoding
RNA gas5 is a growth arrest- and starvation-associated repressor of the
glucocorticoid receptor. Sci Signal 3: ra8.

58.

Bussemakers, M. J., A. van Bokhoven, G. W. Verhaegh, F. P. Smit, H. F.
Karthaus, J. A. Schalken, F. M. Debruyne, N. Ru, and W. B. Isaacs. 1999.
DD3: a new prostate-specific gene, highly overexpressed in prostate cancer.
Cancer Res 59: 5975-5979.

111

59.

Crawford, E. D., K. O. Rove, E. J. Trabulsi, J. Qian, K. P. Drewnowska, J. C.
Kaminetsky, T. K. Huisman, M. L. Bilowus, S. J. Freedman, W. L. Glover, Jr.,
and D. G. Bostwick. 2012. Diagnostic performance of PCA3 to detect prostate
cancer in men with increased prostate specific antigen: a prospective study of
1,962 cases. J Urol 188: 1726-1731.

60.

Chen, J., Z. Miao, B. Xue, Y. Shan, G. Weng, and B. Shen. 2016. Long Noncoding RNAs in Urologic Malignancies: Functional Roles and Clinical
Translation. J Cancer 7: 1842-1855.

61.

Barsyte-Lovejoy, D., S. K. Lau, P. C. Boutros, F. Khosravi, I. Jurisica, I. L.
Andrulis, M. S. Tsao, and L. Z. Penn. 2006. The c-Myc oncogene directly
induces the H19 noncoding RNA by allele-specific binding to potentiate
tumorigenesis. Cancer Res 66: 5330-5337.

62.

Ying, L., Q. Chen, Y. Wang, Z. Zhou, Y. Huang, and F. Qiu. 2012.
Upregulated MALAT-1 contributes to bladder cancer cell migration by
inducing epithelial-to-mesenchymal transition. Mol Biosyst 8: 2289-2294.

63.

Han, Y., Y. Liu, Y. Gui, and Z. Cai. 2013. Long intergenic non-coding RNA
TUG1 is overexpressed in urothelial carcinoma of the bladder. J Surg Oncol
107: 555-559.

64.

Yang, C., X. Li, Y. Wang, L. Zhao, and W. Chen. 2012. Long non-coding RNA
UCA1 regulated cell cycle distribution via CREB through PI3-K dependent
pathway in bladder carcinoma cells. Gene 496: 8-16.

65.

Wang, X. S., Z. Zhang, H. C. Wang, J. L. Cai, Q. W. Xu, M. Q. Li, Y. C. Chen,
X. P. Qian, T. J. Lu, L. Z. Yu, Y. Zhang, D. Q. Xin, Y. Q. Na, and W. F. Chen.

112

2006. Rapid identification of UCA1 as a very sensitive and specific unique
marker for human bladder carcinoma. Clin Cancer Res 12: 4851-4858.
66.

Wang, F., X. Li, X. Xie, L. Zhao, and W. Chen. 2008. UCA1, a non-proteincoding RNA up-regulated in bladder carcinoma and embryo, influencing cell
growth and promoting invasion. FEBS Lett 582: 1919-1927.

67.

Wang, Y., W. Chen, C. Yang, W. Wu, S. Wu, X. Qin, and X. Li. 2012. Long
non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of
bladder cancer. Int J Oncol 41: 276-284.

68.

Zhou, Y., Y. Zhong, Y. Wang, X. Zhang, D. L. Batista, R. Gejman, P. J.
Ansell, J. Zhao, C. Weng, and A. Klibanski. 2007. Activation of p53 by MEG3
non-coding RNA. J Biol Chem 282: 24731-24742.

69.

Zhou, Y., X. Zhang, and A. Klibanski. 2012. MEG3 noncoding RNA: a tumor
suppressor. J Mol Endocrinol 48: R45-53.

70.

Ying, L., Y. Huang, H. Chen, Y. Wang, L. Xia, Y. Chen, Y. Liu, and F. Qiu.
2013. Downregulated MEG3 activates autophagy and increases cell
proliferation in bladder cancer. Mol Biosyst 9: 407-411.

71.

Srivastava, A. K., P. K. Singh, S. K. Rath, D. Dalela, M. M. Goel, and M. L.
Bhatt. 2014. Appraisal of diagnostic ability of UCA1 as a biomarker of
carcinoma of the urinary bladder. Tumour Biol 35: 11435-11442.

72.

Baldassarre, A., and A. Masotti. 2012. Long non-coding RNAs and p53
regulation. Int J Mol Sci 13: 16708-16717.

113

73.

Ritchie, M. E., B. Phipson, D. Wu, Y. Hu, C. W. Law, W. Shi, and G. K.
Smyth. 2015. limma powers differential expression analyses for RNAsequencing and microarray studies. Nucleic Acids Res 43: e47.

74.

Wilkerson, M. D., and D. N. Hayes. 2010. ConsensusClusterPlus: a class
discovery tool with confidence assessments and item tracking. Bioinformatics
26: 1572-1573.

75.

McCarthy, D. J., Y. Chen, and G. K. Smyth. 2012. Differential expression
analysis of multifactor RNA-Seq experiments with respect to biological
variation. Nucleic Acids Res 40: 4288-4297.

76.

Robinson, M. D., D. J. McCarthy, and G. K. Smyth. 2010. edgeR: a
Bioconductor package for differential expression analysis of digital gene
expression data. Bioinformatics 26: 139-140.

77.

Tibshirani, R., T. Hastie, B. Narasimhan, and G. Chu. 2002. Diagnosis of
multiple cancer types by shrunken centroids of gene expression. Proc Natl
Acad Sci U S A 99: 6567-6572.

78.

Lee, W. P., M. P. Stromberg, A. Ward, C. Stewart, E. P. Garrison, and G. T.
Marth. 2014. MOSAIK: a hash-based algorithm for accurate next-generation
sequencing short-read mapping. PLoS One 9: e90581.

79.

Anders, S., and W. Huber. 2010. Differential expression analysis for
sequence count data. Genome Biol 11: R106.

80.

Lerner, S. P., D. J. McConkey, K. A. Hoadley, K. S. Chan, W. Y. Kim, F.
Radvanyi, M. Hoglund, and F. X. Real. 2016. Bladder Cancer Molecular
Taxonomy: Summary from a Consensus Meeting. Bladder Cancer 2: 37-47.

114

81.

McConkey, D. J., W. Choi, A. Ochoa, A. Siefker-Radtke, B. Czerniak, and C.
P. Dinney. 2015. Therapeutic opportunities in the intrinsic subtypes of
muscle-invasive bladder cancer. Hematol Oncol Clin North Am 29: 377-394,
x-xi.

82.

Mlcochova, H., R. Hezova, M. Stanik, and O. Slaby. 2014. Urine microRNAs
as potential noninvasive biomarkers in urologic cancers. Urol Oncol 32: 41
e41-49.

83.

Mengual, L., J. J. Lozano, M. Ingelmo-Torres, C. Gazquez, M. J. Ribal, and A.
Alcaraz. 2013. Using microRNA profiling in urine samples to develop a noninvasive test for bladder cancer. Int J Cancer 133: 2631-2641.

84.

Shah, M. Y., and G. A. Calin. 2011. MicroRNAs miR-221 and miR-222: a new
level of regulation in aggressive breast cancer. Genome Med 3: 56.

85.

Lin, R. J., D. W. Xiao, L. D. Liao, T. Chen, Z. F. Xie, W. Z. Huang, W. S.
Wang, T. F. Jiang, B. L. Wu, E. M. Li, and L. Y. Xu. 2012. MiR-142-3p as a
potential prognostic biomarker for esophageal squamous cell carcinoma. J
Surg Oncol 105: 175-182.

86.

Nassirpour, R., P. P. Mehta, S. M. Baxi, and M. J. Yin. 2013. miR-221
promotes tumorigenesis in human triple negative breast cancer cells. PLoS
One 8: e62170.

87.

Pinatel, E. M., F. Orso, E. Penna, D. Cimino, A. R. Elia, P. Circosta, P.
Dentelli, M. F. Brizzi, P. Provero, and D. Taverna. 2014. miR-223 is a
coordinator of breast cancer progression as revealed by bioinformatics
predictions. PLoS One 9: e84859.

115

88.

Mattiske, S., R. J. Suetani, P. M. Neilsen, and D. F. Callen. 2012. The
oncogenic role of miR-155 in breast cancer. Cancer Epidemiol Biomarkers
Prev 21: 1236-1243.

89.

Esau, C., X. Kang, E. Peralta, E. Hanson, E. G. Marcusson, L. V.
Ravichandran, Y. Sun, S. Koo, R. J. Perera, R. Jain, N. M. Dean, S. M.
Freier, C. F. Bennett, B. Lollo, and R. Griffey. 2004. MicroRNA-143 regulates
adipocyte differentiation. J Biol Chem 279: 52361-52365.

90.

Hamam, D., D. Ali, M. Kassem, A. Aldahmash, and N. M. Alajez. 2015.
microRNAs as regulators of adipogenic differentiation of mesenchymal stem
cells. Stem Cells Dev 24: 417-425.

91.

Guan, X., Y. Gao, J. Zhou, J. Wang, F. Zheng, F. Guo, A. Chang, X. Li, and
B. Wang. 2015. miR-223 Regulates Adipogenic and Osteogenic
Differentiation of Mesenchymal Stem Cells Through a C/EBPs/miR223/FGFR2 Regulatory Feedback Loop. Stem Cells 33: 1589-1600.

92.

Jiang, H., L. Qu, Y. Wang, J. Cong, W. Wang, and X. Yang. 2014. miR-99a
promotes proliferation targeting FGFR3 in human epithelial ovarian cancer
cells. Biomed Pharmacother 68: 163-169.

93.

Xu, N., P. Brodin, T. Wei, F. Meisgen, L. Eidsmo, N. Nagy, L. Kemeny, M.
Stahle, E. Sonkoly, and A. Pivarcsi. 2011. MiR-125b, a microRNA
downregulated in psoriasis, modulates keratinocyte proliferation by targeting
FGFR2. J Invest Dermatol 131: 1521-1529.

94.

Scott, G. K., A. Goga, D. Bhaumik, C. E. Berger, C. S. Sullivan, and C. C.
Benz. 2007. Coordinate suppression of ERBB2 and ERBB3 by enforced

116

expression of micro-RNA miR-125a or miR-125b. J Biol Chem 282: 14791486.
95.

Dou, C., Y. Wang, C. Li, Z. Liu, Y. Jia, Q. Li, W. Yang, Y. Yao, Q. Liu, and K.
Tu. 2015. MicroRNA-212 suppresses tumor growth of human hepatocellular
carcinoma by targeting FOXA1. Oncotarget 6: 13216-13228.

96.

Stern, D. F. 2000. Tyrosine kinase signalling in breast cancer: ErbB family
receptor tyrosine kinases. Breast Cancer Res 2: 176-183.

97.

Cantile, M., R. Franco, G. Schiavo, A. Procino, L. Cindolo, G. Botti, and C.
Cillo. 2011. The HOX genes network in uro-genital cancers: mechanisms and
potential therapeutic implications. Curr Med Chem 18: 4872-4884.

98.

Millar, N. L., D. S. Gilchrist, M. Akbar, J. H. Reilly, S. C. Kerr, A. L. Campbell,
G. A. Murrell, F. Y. Liew, M. Kurowska-Stolarska, and I. B. McInnes. 2015.
MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease.
Nat Commun 6: 6774.

99.

Ogawa, T., M. Iizuka, Y. Sekiya, K. Yoshizato, K. Ikeda, and N. Kawada.
2010. Suppression of type I collagen production by microRNA-29b in cultured
human stellate cells. Biochem Biophys Res Commun 391: 316-321.

100.

Rebouissou, S., I. Bernard-Pierrot, A. de Reynies, M. L. Lepage, C. Krucker,
E. Chapeaublanc, A. Herault, A. Kamoun, A. Caillault, E. Letouze, N.
Elarouci, Y. Neuzillet, Y. Denoux, V. Molinie, D. Vordos, A. Laplanche, P.
Maille, P. Soyeux, K. Ofualuka, F. Reyal, A. Biton, M. Sibony, X. Paoletti, J.
Southgate, S. Benhamou, T. Lebret, Y. Allory, and F. Radvanyi. 2014. EGFR

117

as a potential therapeutic target for a subset of muscle-invasive bladder
cancers presenting a basal-like phenotype. Sci Transl Med 6: 244ra291.
101.

Choi, W., B. Czerniak, A. Ochoa, X. Su, A. Siefker-Radtke, C. Dinney, and D.
J. McConkey. 2014. Intrinsic basal and luminal subtypes of muscle-invasive
bladder cancer. Nat Rev Urol 11: 400-410.

102.

Chen, G., J. Peng, W. Zhu, G. Tao, Y. Song, X. Zhou, and W. Wang. 2014.
Combined downregulation of microRNA-133a and microRNA-133b predicts
chemosensitivity of patients with esophageal squamous cell carcinoma
undergoing paclitaxel-based chemotherapy. Med Oncol 31: 263.

103.

Naito, Y., N. Sakamoto, N. Oue, M. Yashiro, K. Sentani, K. Yanagihara, K.
Hirakawa, and W. Yasui. 2014. MicroRNA-143 regulates collagen type III
expression in stromal fibroblasts of scirrhous type gastric cancer. Cancer Sci
105: 228-235.

104.

Akbari Moqadam, F., E. A. Lange-Turenhout, I. M. Aries, R. Pieters, and M. L.
den Boer. 2013. MiR-125b, miR-100 and miR-99a co-regulate vincristine
resistance in childhood acute lymphoblastic leukemia. Leuk Res 37: 13151321.

105.

McConkey, D. J., W. Choi, Y. Shen, I. L. Lee, S. Porten, S. F. Matin, A. M.
Kamat, P. Corn, R. E. Millikan, C. Dinney, B. Czerniak, and A. O. SiefkerRadtke. 2016. A Prognostic Gene Expression Signature in the Molecular
Classification of Chemotherapy-naive Urothelial Cancer is Predictive of
Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of

118

Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with
Bevacizumab in Urothelial Cancer. Eur Urol 69: 855-862.
106.

Nohata, N., T. Hanazawa, H. Enokida, and N. Seki. 2012. microRNA-1/133a
and microRNA-206/133b clusters: dysregulation and functional roles in
human cancers. Oncotarget 3: 9-21.

107.

Chen, S., X. Chen, Y. L. Xiu, K. X. Sun, Z. H. Zong, and Y. Zhao. 2014.
microRNA 490-3P enhances the drug-resistance of human ovarian cancer
cells. J Ovarian Res 7: 84.

108.

Dadhania, V., M. Zhang, L. Zhang, J. Bondaruk, T. Majewski, A. SiefkerRadtke, C. C. Guo, C. Dinney, D. E. Cogdell, S. Zhang, S. Lee, J. G. Lee, J.
N. Weinstein, K. Baggerly, D. McConkey, and B. Czerniak. 2016. MetaAnalysis of the Luminal and Basal Subtypes of Bladder Cancer and the
Identification of Signature Immunohistochemical Markers for Clinical Use.
EBioMedicine 12: 105-117.

109.

Ponting, C. P., P. L. Oliver, and W. Reik. 2009. Evolution and functions of
long noncoding RNAs. Cell 136: 629-641.

110.

Geisler, S., and J. Coller. 2013. RNA in unexpected places: long non-coding
RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol 14: 699-712.

111.

Prensner, J. R., and A. M. Chinnaiyan. 2011. The emergence of lncRNAs in
cancer biology. Cancer Discov 1: 391-407.

112.

Tano, K., and N. Akimitsu. 2012. Long non-coding RNAs in cancer
progression. Front Genet 3: 219.

119

113.

Nana-Sinkam, S. P., and C. M. Croce. 2011. Non-coding RNAs in cancer
initiation and progression and as novel biomarkers. Mol Oncol 5: 483-491.

114.

Ochoa, A. E., W. Choi, X. Su, A. Siefker-Radtke, B. Czerniak, C. Dinney, and
D. J. McConkey. 2016. Specific micro-RNA expression patterns distinguish
the basal and luminal subtypes of muscle-invasive bladder cancer.
Oncotarget 7: 80164-80174.

115.

Charafe-Jauffret, E., C. Ginestier, F. Monville, P. Finetti, J. Adelaide, N.
Cervera, S. Fekairi, L. Xerri, J. Jacquemier, D. Birnbaum, and F. Bertucci.
2006. Gene expression profiling of breast cell lines identifies potential new
basal markers. Oncogene 25: 2273-2284.

116.

Subramanian, M., P. Francis, S. Bilke, X. L. Li, T. Hara, X. Lu, M. F. Jones, R.
L. Walker, Y. Zhu, M. Pineda, C. Lee, L. Varanasi, Y. Yang, L. A. Martinez, J.
Luo, S. Ambs, S. Sharma, L. M. Wakefield, P. S. Meltzer, and A. Lal. 2015. A
mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion
and metastasis. Oncogene 34: 1094-1104.

117.

Cui, X., X. Jing, C. Long, J. Tian, and J. Zhu. 2017. Long noncoding RNA
MEG3, a potential novel biomarker to predict the clinical outcome of cancer
patients: a meta-analysis. Oncotarget.

118.

Jaeger, J., D. Koczan, H. J. Thiesen, S. M. Ibrahim, G. Gross, R. Spang, and
M. Kunz. 2007. Gene expression signatures for tumor progression, tumor
subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin
Cancer Res 13: 806-815.

120

119.

Jin, C., Y. Zheng, Y. Huang, Y. Liu, L. Jia, and Y. Zhou. 2017. Long noncoding RNA MIAT knockdown promotes osteogenic differentiation of human
adipose-derived stem cells. Cell Biol Int 41: 33-41.

120.

Lindgren, D., F. Liedberg, A. Andersson, G. Chebil, S. Gudjonsson, A. Borg,
W. Mansson, T. Fioretos, and M. Hoglund. 2006. Molecular characterization
of early-stage bladder carcinomas by expression profiles, FGFR3 mutation
status, and loss of 9q. Oncogene 25: 2685-2696.

121.

Zhou, J., W. Li, T. Jin, X. Xiang, M. Li, J. Wang, G. Li, X. Pan, and D. Lei.
2015. Gene microarray analysis of lncRNA and mRNA expression profiles in
patients with hypopharyngeal squamous cell carcinoma. Int J Clin Exp Med 8:
4862-4882.

122.

Darda, L., F. Hakami, R. Morgan, C. Murdoch, D. W. Lambert, and K. D.
Hunter. 2015. The role of HOXB9 and miR-196a in head and neck squamous
cell carcinoma. PLoS One 10: e0122285.

123.

Wang, Y. L., Y. Bai, W. J. Yao, L. Guo, and Z. M. Wang. 2015. Expression of
long non-coding RNA ZEB1-AS1 in esophageal squamous cell carcinoma
and its correlation with tumor progression and patient survival. Int J Clin Exp
Pathol 8: 11871-11876.

124.

Lee, Y. B., I. Bantounas, D. Y. Lee, L. Phylactou, M. A. Caldwell, and J. B.
Uney. 2009. Twist-1 regulates the miR-199a/214 cluster during development.
Nucleic Acids Res 37: 123-128.

121

125.

Xin, W., X. Liu, J. Ding, J. Zhao, Y. Zhou, Q. Wu, and K. Hua. 2015. Long
non-coding RNA derived miR-205-5p modulates human endometrial cancer
by targeting PTEN. Am J Transl Res 7: 2433-2441.

126.

Yin, D. D., Z. J. Liu, E. Zhang, R. Kong, Z. H. Zhang, and R. H. Guo. 2015.
Decreased expression of long noncoding RNA MEG3 affects cell proliferation
and predicts a poor prognosis in patients with colorectal cancer. Tumour Biol
36: 4851-4859.

127.

Sun, M., R. Xia, F. Jin, T. Xu, Z. Liu, W. De, and X. Liu. 2014. Downregulated
long noncoding RNA MEG3 is associated with poor prognosis and promotes
cell proliferation in gastric cancer. Tumour Biol 35: 1065-1073.

128.

Shen, Y., L. F. Dong, R. M. Zhou, J. Yao, Y. C. Song, H. Yang, Q. Jiang, and
B. Yan. 2016. Role of long non-coding RNA MIAT in proliferation, apoptosis
and migration of lens epithelial cells: a clinical and in vitro study. J Cell Mol
Med 20: 537-548.

129.

Song, W., Y. Y. Liu, J. J. Peng, H. H. Liang, H. Y. Chen, J. H. Chen, W. L. He,
J. B. Xu, S. R. Cai, and Y. L. He. 2016. Identification of differentially
expressed signatures of long non-coding RNAs associated with different
metastatic potentials in gastric cancer. J Gastroenterol 51: 119-129.

130.

Wang, P., J. Cui, J. Wen, Y. Guo, L. Zhang, and X. Chen. 2016. Cisplatin
induces HepG2 cell cycle arrest through targeting specific long noncoding
RNAs and the p53 signaling pathway. Oncol Lett 12: 4605-4612.

122

131.

Fan, Y., B. Shen, M. Tan, X. Mu, Y. Qin, F. Zhang, and Y. Liu. 2014. Long
non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by
regulating Wnt signaling. FEBS J 281: 1750-1758.

132.

Xue, M., X. Li, W. Wu, S. Zhang, S. Wu, Z. Li, and W. Chen. 2014.
Upregulation of long non-coding RNA urothelial carcinoma associated 1 by
CCAAT/enhancer binding protein alpha contributes to bladder cancer cell
growth and reduced apoptosis. Oncol Rep 31: 1993-2000.

133.

Xue, M., H. Pang, X. Li, H. Li, J. Pan, and W. Chen. 2016. Long non-coding
RNA urothelial cancer-associated 1 promotes bladder cancer cell migration
and invasion by way of the hsa-miR-145-ZEB1/2-FSCN1 pathway. Cancer
Sci 107: 18-27.

134.

Baffa, R., M. Fassan, S. Volinia, B. O'Hara, C. G. Liu, J. P. Palazzo, M.
Gardiman, M. Rugge, L. G. Gomella, C. M. Croce, and A. Rosenberg. 2009.
MicroRNA expression profiling of human metastatic cancers identifies cancer
gene targets. J Pathol 219: 214-221.

135.

Hui, A. B., W. Shi, P. C. Boutros, N. Miller, M. Pintilie, T. Fyles, D. McCready,
D. Wong, K. Gerster, L. Waldron, I. Jurisica, L. Z. Penn, and F. F. Liu. 2009.
Robust global micro-RNA profiling with formalin-fixed paraffin-embedded
breast cancer tissues. Lab Invest 89: 597-606.

136.

Geraldo, M. V., A. S. Yamashita, and E. T. Kimura. 2012. MicroRNA miR146b-5p regulates signal transduction of TGF-beta by repressing SMAD4 in
thyroid cancer. Oncogene 31: 1910-1922.

123

137.

Deng, X., B. Wu, K. Xiao, J. Kang, J. Xie, X. Zhang, and Y. Fan. 2015. MiR146b-5p promotes metastasis and induces epithelial-mesenchymal transition
in thyroid cancer by targeting ZNRF3. Cell Physiol Biochem 35: 71-82.

138.

Schwickert, A., E. Weghake, K. Bruggemann, A. Engbers, B. F. Brinkmann,
B. Kemper, J. Seggewiss, C. Stock, K. Ebnet, L. Kiesel, C. Riethmuller, and
M. Gotte. 2015. microRNA miR-142-3p Inhibits Breast Cancer Cell
Invasiveness by Synchronous Targeting of WASL, Integrin Alpha V, and
Additional Cytoskeletal Elements. PLoS One 10: e0143993.

139.

Lu, Y., N. Ji, W. Wei, W. Sun, X. Gong, and X. Wang. 2017. MiR-142
modulates human pancreatic cancer proliferation and invasion by targeting
hypoxia-inducible factor 1 (HIF-1alpha) in the tumor microenvironments. Biol
Open 6: 252-259.

140.

Ebert, M. S., and P. A. Sharp. 2010. Emerging roles for natural microRNA
sponges. Curr Biol 20: R858-861.

141.

Xia, T., Q. Liao, X. Jiang, Y. Shao, B. Xiao, Y. Xi, and J. Guo. 2014. Long
noncoding RNA associated-competing endogenous RNAs in gastric cancer.
Sci Rep 4: 6088.

142.

Rodriguez, A., S. Griffiths-Jones, J. L. Ashurst, and A. Bradley. 2004.
Identification of mammalian microRNA host genes and transcription units.
Genome Res 14: 1902-1910.

143.

Keniry, A., D. Oxley, P. Monnier, M. Kyba, L. Dandolo, G. Smits, and W. Reik.
2012. The H19 lincRNA is a developmental reservoir of miR-675 that
suppresses growth and Igf1r. Nat Cell Biol 14: 659-665.

124

VITA
Andrea Elizabeth Ochoa was born in McAllen, Texas on June 12, 1990, the
daughter of Imelda Ramirez Ochoa and Eli Rene Ochoa. After completing her work
at South Texas High School for Health Professions, Mercedes, Texas in 2008, she
entered St. Edward’s University in Austin, Texas. She received the degree of
Bachelor of Science with a major in Bioinformatics and a specialization in
Biomathematics from St. Edward's University in May 2011. In August of 2011 she
entered The University of Texas MD Anderson Cancer UTHealth Graduate School of
Biomedical Sciences.

125

